Pyroglutamylated amyloid beta peptides enhance non-fibrillogenic aggregation of the unmodified peptide by Goldblatt, Gregory
University of Central Florida 
STARS 
Electronic Theses and Dissertations, 2004-2019 
2016 
Pyroglutamylated amyloid beta peptides enhance non-fibrillogenic 
aggregation of the unmodified peptide 
Gregory Goldblatt 
University of Central Florida 
 Part of the Biology Commons 
Find similar works at: https://stars.library.ucf.edu/etd 
University of Central Florida Libraries http://library.ucf.edu 
This Doctoral Dissertation (Open Access) is brought to you for free and open access by STARS. It has been accepted 
for inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more 
information, please contact STARS@ucf.edu. 
STARS Citation 
Goldblatt, Gregory, "Pyroglutamylated amyloid beta peptides enhance non-fibrillogenic aggregation of the 
unmodified peptide" (2016). Electronic Theses and Dissertations, 2004-2019. 4865. 
https://stars.library.ucf.edu/etd/4865 
PYROGLUTAMYLATED AMYLOID BETA PEPTIDES ENHANCE NON-
FIBRILLOGENIC AGGREGATION OF THE UNMODIFIED PEPTIDE 





by 
 
 
 
 
 
GREGORY L. GOLDBLATT 
B.S. University of Central Florida, 2012 
M.S. University of Central Florida, 2015 
 
 
A dissertation submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy 
in the Burnett School of Biomedical Sciences 
in the College of Medicine 
at the University of Central Florida 
Orlando, Florida 
 
 
 
 
 
 
 
Spring Term 
2016 
 
 
 
 
 
 
 
Major Professor: Suren A. Tatulian 
 
 
ii 
 
 
 
 
 
 
 
 
©2016 Gregory Goldblatt 
 
  
iii 
 
ABSTRACT 
Alzheimer’s disease (AD) is accompanied by abnormal extracellular deposition of 
amyloid  (A) peptide. This has led to the amyloid cascade hypothesis, causatively 
relating A with AD. While A deposits assume a fibrillar cross- structure, prefibrillar 
oligomers of A have been identified as the main cytotoxic agents in AD. 
Pyroglutamylated amyloid beta (ApE) peptides are N-terminally truncated and 
pyroglutamylated (at Glu3 or Glu11) A molecules that display enhanced cytotoxicity 
and represent up to 50% of total A in AD brains. ApE significantly enhances the 
toxicity of unmodified A by an unknown mechanism. Although in situ A populations 
are heterogeneous, the majority of studies have been conducted on single A species.  
Here, we examined the structural and morphological changes that occur in mixed 
A/ApE samples. Circular dichroism and transmission electron microscopy data 
indicate that ApE3-42 forms -sheet structure and undergoes delayed fibrillogenesis 
compared to unmodified A1-42. Further, ApE3-42 decelerates -sheet formation in mixed 
A1-42/ApE3-42 samples. FTIR measurements, using 13C-labeled A1-42 and unlabeled 
ApE3-42, indicate that ApE3-42 inhibits cross--sheet formation by A1-42, which explains 
the retardation of fibrillogenesis. FTIR on peptides 13C-labeled at specific segments 
provided site specific structural information. Based on these data, the monomeric A 
structure has been modeled as a -hairpin stabilized by intramolecular H-bonding with an 
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N-terminal -helix. These hairpins likely form higher order aggregates through ionic and 
hydrophobic interactions between the C-terminus of one hairpin and the N-terminus of 
another. Utilizing a novel technique, hydration from gas phase, we examined the -helix 
to -sheet transitions of these peptides. When combined, ApE3-42 and A1-42 mutually 
inhibit intermolecular -sheet formation, instead promoting formation of ApE3-42/A1-42 
hetero-oligomers of intramolecular H-bonding.  
These hetero-oligomers displayed enhanced toxicity to PC12 cells compared to 
individual peptides and induced greater calcium release from lipid vesicles than 
unmodified A. These results indicate that A and ApE mutually inhibit fibrillogenesis 
and stabilize hetero-oligomers of enhanced cytotoxicity, possibly through a membrane 
permeabilization mechanism. Collectively, our findings lead to a new concept that 
A/ApE hetero-oligomers, not just A or ApE oligomers, are the main cytotoxic 
species in AD.
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CHAPTER ONE: INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disease affecting more than 35 million 
people worldwide. The primary symptom of AD is progressive loss of memory and other cognitive 
faculties leading to death within 3-9 years of diagnoses (1). AD is the most common form of 
dementia representing over 50% of cases examined at autopsy or clinical series (1). AD primarily 
affects the elderly. The odds of being diagnosed with AD double every 5 years after the age of 65,  
and the odds of receiving a positive diagnosis after the age of 85 is 1:3 (2). Due to an aging 
population, the number of cases of AD in the United States is rising rapidly. By 2050 there will be 
an estimated 13 million cases representing a yearly economic cost of $1 trillion (3). 
Effective treatments for AD are lacking and the success rate of AD drugs in clinical trials 
falls below 1% (4). There is significant loss of neuronal synapses in AD correlating closely with 
cognitive symptoms and predating neuronal death (5). Familial Alzheimer disease (FAD) is caused 
by genetic mutation with symptoms generally appearing in the early 40s. Sporadic Alzheimer 
disease (SAD), which makes up the majority of AD cases, usually manifests after the age of 65. 
FAD and SAD are indistinguishable from one another histologically. The two main hallmarks of 
AD are beta amyloid plaques and neurofibrillary tangles (NFTs). Plaques are extracellular protein 
aggregates composed of the A peptide; NFTs are intracellular aggregates consisting largely of 
hyper-phosphorylated tau. A peptides are small, hydrophobic peptides of no known physiological 
function, while tau normally associates with microtubules. 
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The amyloid cascade hypothesis states that AD is a consequence of the buildup of A 
peptides, through either increased production or decreased clearance (6). Evidence points to 
soluble aggregates of A as the cytotoxic species in AD (7, 8).  
Amyloid Beta Peptide 
A peptides are formed by cleavage of the amyloid precursor protein (APP) a 
transmembrane glycoprotein. The N-terminus of the APP is in extracellular space, while the C-
terminus terminates within the cytosol. The exact function of the APP is unknown, but it is believed 
to play a role in cell growth and proliferation, as well as influencing synaptogenesis (9). In the 
non-amyloidogenic pathway, the APP is cleaved by -secretase in the middle of the amyloid beta 
transmembrane segment creating the C83 fragment. The C83 fragment is then cleaved by -
secretase forming the APP Intracellular Domain (AICD) and a truncated A fragment known as 
p3 (9-11). The AICD enters the cytosol and is believed to play a role in nuclear signaling while 
the p3 seems pathologically irrelevant. Interaction between -secretase and the APP can lead to 
amyloidogenic cleavage at D672 freeing the N-terminus of the A and creating the C99 fragment 
(12). The C99 fragment is then cleaved by -secretase freeing the A peptide and forming the 
AICD (8, 10). This cleavage most frequently occurs at V40 forming the A40 fragment, but 
cleavage also occurs at nearby A42 and G38 positions on the C99 forming the A42 and A1-38 
respectively (12-14). The A peptide leaves the membrane and enters the extracellular space 
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following cleavage (10, 11, 14). Most mutations associated with FAD are associated with A 
production and involve the APP or its processing (15-19). There are many different species of A 
peptide and in situ A populations are heterogeneous (13, 20). Although the most common A 
found in the brain is the A1-40 the A1-42 is most often associated with AD (13, 21). Additionally, 
pyroglutamylated A is a major species in the AD brain and has been found to make up to 50% of 
the soluble A load (13, 20, 22). Amyloid beta builds up intracellularly as well, through production 
at either the endoplasmic reticulum (ER) or vesicles, as well as re uptake of oligomers (23-26). 
The intracellular buildup of A often precedes extracellular increases in A concentration and 
onset of synaptic dysfunction (24, 25). 
Current Issues in AD 
 No current treatments exist that delay the progression of AD. Currently, five drugs are FDA 
approved for the treatment of AD, the cholinesterase inhibitors: Tacrine, Donepezil, Revastigmine, 
and Galantamine; and the N-methyl-D-aspartate (NMDA) receptor antagonist Memantine. There 
have been no new AD drugs approved since 2003 (4).  Between 2002 and 2012, only one of the 
230 compounds assessed for the treatment of AD passed phase 3 clinical trials and was approved 
for treatment(4). This failure rate of 99.6% is the highest of any therapeutic area (27, 28). High 
profile AD drug failures include the anti A monoclonal antibody drugs bapineuzumab and 
solanezumab. As well as the A reducing drugs Phenserine, which reduces APP expression (29), 
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and Flurizan, which reduces A1-42 levels, likely through a mechanism involving -secretase (30, 
31). Data has not been released as to whether these drugs failed to have an effect on A load, or 
whether they decreased A load, but there was no corresponding decrease in cognitive decline. 
The failure of these drugs to translate from animal models into humans calls into question the 
accuracy of existing AD models and necessitates re-evaluation of the amyloid cascade hypothesis. 
Shortcomings of the Amyloid Cascade Hypothesis 
In the decades since the amyloid cascade hypothesis was first postulated, many new 
discoveries have been made. (32-35). Recent findings have shifted focus from insoluble fibrils to 
soluble oligomers of A as the main cytotoxic entity in AD. Soluble oligomers of A have been 
shown to inhibit long-term potentiation (LPT), and the population of soluble oligomers is an 
accurate predictor of synaptic decline (7, 8, 23, 36-39). Additionally, plaque levels do not correlate 
with disease state and are found in the brains of cognitively normal patients (40, 41). In fact, 
cognitive impairment in AD correlates better with tangle burden than plaque levels (42). 
Additionally, studies have found A neurotoxicity to be tau dependent, both in vivo and in vitro 
casting doubt on the completeness of the amyloid cascade hypothesis (43-45). Studies have shown 
oligomers to be significantly more cytotoxic than fibrils (46, 47). Some of these oligomers may be 
intermediates of fibrillogenesis, however others are formed via distinct pathways (48, 49). 
Neurotoxic oligomers appear to propagate via a prion-like mechanism, with pyroglutamylated 
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amyloid beta (ApE) in particular having a profound effect on toxicity even at low molar ratios 
(44, 50, 51). Dot blot experiments have shown that hybrid ApE3-42:A1-42 oligomers and similar 
sized oligomers formed by A1-42 alone are distinct structurally with hybrid oligomers having 
significantly enhanced toxicity (44). Surprisingly, A monomers appear neuroprotective, against 
both oxidative stress as well as the absence of insulin (52, 53). A40 has demonstrated a protective 
effect by inhibition of A1-42 aggregation (52). These findings necessitate the altering of the 
amyloid cascade hypothesis, shifting focus from large fibrillar aggregates to small soluble 
oligomers of A. An illustration of this refined amyloid cascade where oligomers formed as 
intermediates during fibrillogenesis or via other aggregation pathways lead to AD is shown in 
Figure 1. Little is known about the A peptide following cleavage from the membrane and prior 
to formation of proto-fibrils. 
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Figure 1. Potential pathway for the pathogenesis of AD via A oligomers. Little is known about the aspects of this 
pathway contained within the blue box. 
Pyroglutamylated Amyloid Beta 
The N-truncated, N-modified pyroglutamylated A (ApE) is a major A species in the 
AD brain and can make up as much as 50% of total soluble A load (13, 20, 22, 54). 
Pyroglutamylation occurs when glutamic acid is at the N-terminus of the peptide, most often due 
to upstream aminopeptidase degradation. The N-terminal glutamic acid is then cyclized in a 
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dehydration reaction carried out via glutaminyl cyclase (QC) (55). Pyroglutamylated A are 
believed to be highly involved in the pathogenesis of AD (20, 44, 54, 56). A population changes 
over time with the fraction of ApE increasing with disease progression (20, 57). In addition, QC 
expression is found in the peripheral blood of AD patients (58). The most common ApE is the 
ApE3-42 fragment, however ApE11-42, ApE3-40, and ApE11-40 have all been observed in AD brains 
(20, 59, 60).  
Over expression of QC in mice was found to cause behavioral deficits while knockout or 
inhibition of QC had a rescue effect (55, 61). Loss of calcium homeostasis, an early event in AD, 
has been shown to increase QC expression leading to an increased in ApE production (62). 
Studies indicate that ApE has altered aggregation, forming greater numbers and longer lived 
oligomers compared to unmodified A (63, 64). Pyroglutamylated A and hybrid A1-42/ApE3-42 
oligomers display increased toxicity when compared to unmodified A (44, 56). Additional studies 
found ApE to be more resistant to astrocyte degradation and have increased cytotoxicity to 
cultured neurons compared to both A1-42 and A1-40 (22). A correlation between ApE and 
adjacent deposits of hyper-phosphorylated tau has been found in AD brains, providing evidence 
of a link between ApE and tau phosphorylation (56). This is strong evidence towards the 
involvement of ApE in AD. 
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Gaps in Knowledge of A Oligomers 
Although they are believed to be the cytotoxic species in A, structural data on A 
oligomers is lacking. Previous structural studies have often used non-physiological conditions 
calling into question the disease relevance of their results (65, 66). Additionally, most structural 
studies have taken place on a single species of A and not a heterogeneous population as is found 
in situ. More detailed structural understandings of A oligomers and early aggregates are 
necessary to better understand the role of these oligomers in the pathogenesis of AD. Of particular 
interest are the changes that occur in mixed samples of ApE and A. This work aimed to 
characterize structural and morphological changes exerted on A by ApE. We found that ApE 
and A mutually inhibit fibrillogenesis by inhibiting intermolecular -sheet formation of one 
another. Instead, in combination they form hetero-oligomers composed of -hairpins which 
aggregate through ionic or hydrophobic bonds of a C-terminus of one hairpin and the N-terminus 
of another. These hetero-oligomers had increased cytotoxicity to PC12 cells. This study highlights 
the importance of A: ApE hetero-oligomers in the pathogenesis of AD. These hetero-oligomers 
may represent a promising target in the search for promising new ways to effectively treat AD.  
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CHAPTER TWO: LITERATURE SEARCH 
Before moving forward with this project, it was necessary to re-evaluate the amyloid 
cascade hypothesis to ensure the pertinence of A peptides in AD. Research was conducted on the 
genetics of AD, as well as the role tau plays in AD. This data supports A peptides as the initiator 
of AD pathology. In addition, current literature was searched on the structure and aggregation of 
A, especially oligomeric A. Finally, as this project related A to the neuronal death associated 
with AD, it is necessary to examine current literature on possible mechanisms of neurotoxicity in 
AD. 
Genetics of AD 
Since the discovery of the first genetic link in AD, multiple genes have been implicated in 
AD, with many mutations found to be fully penetrant. The most prevalent FAD mutations occur 
on the APP, PSEN1, and PSEN2, all genes associated with production of A (67, 68). One of the 
first genes associated with AD was the APP on chromosome 21. Many different mutations have 
been identified on the APP most of them leading to FAD (15, 16, 69, 70). Some APP mutations 
are neuroprotective, and hypothesized mechanisms of protection include: the lowering of A load, 
inhibition of the APP transforming growth factor 2 (TGF2) cell mediated death pathway, or 
through the alteration of aggregation kinetics (15, 71).  
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Conversely, APP mutations implicated in FAD have been linked to: higher A production, 
increased levels of tau, and increases in the A1-42/A1-40 ratio (16, 70). The majority of FAD 
mutations are linked to presenilin protein mutations (17). Mutations have been found for both 
PSEN1 located on chromosome 14 and PSEN2 located on chromosome 1 (17, 18, 72). PSEN 1 
and 2 along with the accessory proteins nicastrin, APH-1, and PEN2 form the -secretase, which 
is responsible for the final cleavage of A from the membrane. The prevailing proposed 
mechanism of PSEN mutations causing FAD is through partial loss in function of -secretase 
activity, leading to only partial processing of A1-42 and increasing the A1-42/A1-40 ratio in the 
brain (19, 68, 73). 
The previously discussed genes have been linked to FAD, which represents <1% of AD 
cases (74). The vast majority of AD cases are SAD, with the strongest known risk factor being 
Apolipoprotein E allele (ApoE). ApoE has multiple isoforms with the E2 being neuroprotective 
and E4 being a risk factor for AD (74). ApoE aids in the degradation of amyloid beta within 
microglial cells, and the ability of astrocytes to clear diffuse A deposits (75-77). Previous studies 
have also demonstrated retardation of blood brain barrier (BBB) clearance of amyloid-ApoE 
aggregates compared to free A via redirection of clearance from the LRP1 to the VLDLR, which 
internalizes A-ApoE complexes more slowly (75). This clearance delay is isoform dependent 
with the E4 allele clearing more slowly than E3 and E2. This clearance slowdown may contribute 
to buildup of amyloid structures on blood vessels and explain the increased risk of cerebral amyloid 
angiopathy (CAA) associated with the E4 allele of ApoE (75). 
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Trisomy 21 and AD 
Due to the location of the APP gene on chromosome 21, there is a strong correlation 
between AD and trisomy 21 or Down syndrome (DS). Two-thirds of full trisomy 21 translocation 
patients develop dementia by the age of 60 (78). Interestingly, this association is only present if 
the APP gene is present on the extra chromosome, granting a third copy of the gene (79, 80). 
Patients without a third copy of APP will have DS without the increased risk of developing AD, 
normally associated with it. Furthermore, translocation of a small fragment of chromosome 21 
causing duplicate APP copies on a single chromosome cause FAD but not DS (69, 81). The 
relationship between an extra copy of APP and AD is strong evidence in support of A as the 
causative agent in AD. 
The Role of Tau in AD 
One of the hallmarks of AD is the presence of intracellular aggregates composed of highly 
phosphorylated tau. Tau is a protein involved in the stabilization of microtubules (5). Tau has 
multiple phosphorylation sites, and increased phosphorylation levels has an inhibitory effect on 
microtubule binding leading to a corresponding increase of soluble tau (82, 83)Phosphorylated tau 
has been shown to closely interact with F-actin causing bundling and aggregation of F-actin 
forming actin rich rods (84). F-actin is present at the dendritic synapse making tau mediated F-
actin aggregation a possible mechanism of synaptic loss in AD (85). The presence of NFTs is 
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linked to a reduction in expression of synaptic vesicle transport proteins. Levels of soluble tau 
correlate with AD implicating soluble tau as the neurotoxic form of tau (83, 86, 87). A has been 
shown to cause dendritic spine loss in the absence of tau; however, neuronal death was tau 
dependent (88).  
Excitotoxicity has been implicated as a mechanism of neuronal death involved in AD (89, 
90). Knockout of tau has been shown to attenuate hyper-excitability in mouse models 
overexpressing A (91). Strong evidence suggests that tau and A act in concert in AD to cause 
synaptic loss and neuronal death (43, 45, 86, 92, 93). However, in the front cortex of AD patients, 
A levels were found to be increased prior to the onset of significant tau pathology (94). 
Additionally, reduction in soluble A levels has been linked to a decrease in tau accumulation. 
Increased levels of A peptides have also been linked to the phosphorylation of tau (82, 93, 95, 
96). A dimers isolated from AD brains induce phosphorylation of tau causing neuritic 
degeneration (97).This evidence suggests that although a strong link between tau and AD exists, 
tau phosphorylation and aggregation is likely a downstream effect of A buildup. This supports 
the case that although tau is intimately linked to AD, buildup of A peptide is likely the initiating 
factor in AD pathogenesis. 
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A Structural Studies 
Consistent with the majority of transmembrane proteins, the amyloid beta segment of the 
APP is -helical prior to cleavage and exit from the lipid membrane. Supporting this is data from 
NMR studies on a segment of the APP containing the A sequence embedded in micelles which 
show the A sequence to form an -helix with a disordered C-terminus (98, 99). Structural changes 
and aggregation commences once the hydrophobic A peptides enter an aqueous environment. 
Amyloid Beta Fibrils 
Both solid-state nuclear magnetic resonance (ssNMR) and X-ray diffraction have shown 
mature amyloid fibrils to possess a cross -structure; meaning the -sheet plane and backbone 
hydrogen bonds connecting -strands are parallel to the main fibril axis while the -strands run 
perpendicular to the fibrillar axis (100, 101). Recently, studies have shown the presence of steric 
zippers in amyloid fibrils (102, 103). Steric-zippers are formed by the C-terminus of pairs of cross 
-sheets with interdigitating side chains (102, 103). TEM studies have shown mature fibrils to 
contain one or more protofilaments and to display two-fold symmetry with the fibril cross section 
superimposing with itself after 180 degree rotation (104-106).  
Studies indicate that amyloid fibrils, formed by both the A1-40 and A1-42, are composed 
of in-register parallel -sheets (107-109). However, fibrils formed by the Iowa mutant A peptide 
can have either parallel or antiparallel architecture (110). A fibrils and oligomers are polymorphic 
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with their internal structure often changing in an environment dependent manner, highlighting the 
importance of utilizing relevant experimental conditions (108). Fibrils seeded by brain extracts of 
AD patients had different structures, indicating that different seeds can induce formation of distinct 
fibrils and that fibril structure is not necessarily consistent between patients (107). A samples 
often show intra-sample polymorphism; meaning that measurements such as NMR and CD 
demonstrate the average and/or most prevalent of the multiple different structures within a sample 
(108). The polymorphic nature of A aggregates complicates the reproducibility of A structural 
data. 
Oligomeric Amyloid Beta 
The toxicity of A oligomers is linked to both oligomer size and structure. Dodecamers of 
A isolated from the brains of Tg2576 mice disrupted the memory of young rats (111). While A 
dimers isolated from the cerebral cortex of AD brains inhibited LPT in rat hippocampal slices and 
impaired memory when injected into rats (112), A dimers, trimers, and tetramers were found to 
inhibit LTP in mouse hippocampal neurons at physiological concentrations, with trimers having 
the greatest effect (38).Ion mobility, coupled with mass spectroscopy experiments, found that A1-
40 monomers form dimers, which then dimerize, and then likely undergo fibrillogenesis while A1-
42 tetramers went on to form hexamers, and then dodecamers (113). 
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It is commonly believed that the toxic species of A are oligomers of mixed -helix/-
sheet content formed during the transition from -helical monomer to cross -sheet fibril (114-
116).The transient nature of these aggregates makes their study difficult, therefore structural data 
on oligomeric A is lacking. Studies that have been conducted on the oligomeric A have found 
presence of both parallel and antiparallel -sheet, along with mixed / structures (117-122). One 
group demonstrated that inhibiting the formation of antiparallel -sheet led to a corresponding 
decline in toxicity (119). Many studies have used non-physiological conditions in order to stabilize 
these oligomers, calling into question the physiological relevance of their findings (49, 66, 115, 
116, 123).  
A Aggregation 
Protein fibrillization is implicated in multiple human diseases including AD, Parkinson’s 
disease, and Huntington’s disease. Fibrillization takes place in three stages: a lag phase during 
which prefibrillar intermediates are formed, a growth phase of rapid fibril growth and elongation, 
and finally growth plateaus once fibrillogenesis reaches equilibrium (124, 125). A fibrillization 
takes place via nucleated growth with the C-terminus being critical in the seeding of fibrillization 
(126-129). The rate of fibrillogenesis is dependent on both pH and temperature (130, 131). Studies 
have indicated that formation of a turn at residues ~23-28 is critical to A fibrillization and toxicity. 
This sequence is home to multiple mutations that lead to FAD, indicating the importance of this 
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turn to the disease state (132). Structural studies indicate that this turn is part of a -hairpin 
structure formed as an intermediate during aggregation (114, 133). Previous studies have found 
ApE to aggregate faster than, and have a higher -sheet propensity than A likely due to 
increased hydrophobicity (125, 134). Conversely, other studies have found that ApE3-42 aggregates 
slower and has lower -sheet propensity (135). Additionally, it was found that ApE3-42 increased 
the lag phase of A1-42 and delayed -sheet formation (135). Further studies are needed to clarify 
fibrillization kinetics of A1-42 and ApE3-42 as well as the effect ApE3-42 has on A1-42 
fibrillogenesis.  
Cell Death in AD 
 There have been many proposed mechanisms of A mediated cytotoxicity. Many different 
mechanisms have been demonstrated in vitro, but more study is needed to ascertain their 
relationship to the disease in vivo. These mechanisms include the alteration of mitochondrial 
dynamics, loss of calcium homeostasis, and trans-nitrosylation of proteins due to increased RNS 
production. 
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Alteration of Mitochondrial Dynamics 
Mitochondrial dynamics, or their constant fission and fusion, is used to dilute 
mitochondrial DNA damage and maintain a healthy mitochondria population (136). Alterations in 
mitochondrial dynamics has been implicated as a mechanism of both synaptic degradation and 
neuronal death in AD.  Neurons are highly energy dependent due to the large energy exertion 
required to maintain synapses, as well as the re-uptake and release of neurotransmitters. Aged 
mitochondria display reduced activity of complex I and IV in the respiration chain (137). 
Mitochondrial DNA mutations accumulate over time due to oxidative species formed during 
respiration (138). Fractionated mitochondria and broken cristae have been found in AD brains, 
indicating a loss of mitochondrial dynamics homeostasis (139). Fragmented mitochondria produce 
less ATP production and more reactive oxidative species (ROS) (136). Oxidative damage has been 
described in lipid membranes and proteins in AD brains, providing evidence for the role altered 
mitochondrial dynamics play in the disease (139, 140). Increases in mitochondrial derived ROS 
have been linked to upregulation of APP increasing A levels in a positive feedback mechanism 
(141). Increased ROS production is also an early signal of apoptosis (142).  Fusion of mitochondria 
is carried out via a complex of mitofusins 1 and 2 and optic atrophy 1 (136, 143). Mitochondrial 
fission is carried out via dynamin-related protein 1 (drp1), which is targeted to the mitochondrial 
outer membrane via: mitochondrial fission factor mitochondrial fission protein 1 and, 
mitochondrial elongation factor 1 (136). Up-regulation of mitochondrial fission in AD is believed 
to be due to increased activity or localization of drp1 due to post-translational modification, 
although the exact mechanism is controversial. Some groups have theorized that this occurs 
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through increased GTPase activity of Drp1 via nitrosylation (144, 145). Other groups argue that 
the altered dynamics is due to increased targeting of drp1 to mitochondria due to phosphorylation 
of drp1 (146). Additionally, enhanced levels of glycogen synthase kinase 3 (GSK3) have been 
found in AD patients (96). GSK3 has been linked to phosphorylation of drp1 upregulating its 
activity, as well as an increase in Cdk5 activity and tau expression (95, 147). 
Loss of Calcium Homeostasis 
Loss of intracellular calcium homeostasis is also implicated in AD neuronal death. Calcium 
is a vital intracellular signaling molecular responsible for regulating many signal cascades. Loss 
of calcium homeostasis has been linked to cellular apoptosis (148). Studies have shown A 
peptides to cause deregulation of calcium homeostasis, providing evidence for it being a 
mechanism of cellular death in AD (149-155).  
There have been many proposed pathways that A affect calcium regulation. A peptides 
have been linked to the upregulation of ryanodine receptors, specifically Ryanodine Receptor 3 
(RyR3) (153-155). These receptors release calcium from the endoplasmic reticulum (ER) in 
response to increases in intracellular calcium termed calcium induced calcium release (CICR). 
Increased levels of tau and A are linked to increased glutamate levels through increased 
expression and inhibition of re-uptake and transport (156-159). Glutamate can activate both RyR3 
and NMDAR increasing intracellular calcium. Soluble A oligomers were found to have high 
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affinity for PrPc. These complexes were found to interact with a complex of mGluR5 and Fyn, 
causing increased NMDAR activity and thus calcium influx (160). It was also found that these 
A-PrPc-mGluR5 complexes mediate dendritic spine loss through eEF2 phosphorylation. 
Additionally, A peptides have been shown to inhibit the activity of mGlu7 an NMDAR regulator 
further increasing NMDAR activation and subsequence calcium influx. Increases in intracellular 
Ca2+ concentrations mediates signaling changes via multiple mechanisms.  In response to increased 
calcium the calcium dependent protease calpain cleaves the Cyclin dependent kinase 5 (Cdk5) 
activators p35 to p25 or p39 to p29, causing aberrant increased Cdk5 activity (161, 162). This 
increased Cdk5 activity has been demonstrated to lead to an increase in A production as well as 
production and hyper-phosphorylation of tau (95, 161, 162).  
Amyloid Pore Formation 
 Another mechanism of loss of calcium homeostasis in AD is the formation of calcium 
permeable channels composed of A in the organelles and plasma membranes of neurons (121, 
149, 163-167). These pores have been observed in AD brains and in vitro assays have 
demonstrated an influx of calcium through A pores at physiological peptide concentrations, 
lending credence to this theory (163, 164, 167). Evidence shows that A behaves similarly to 
gramicidin, an antimicrobial agent which has mostly -sheet structure and forms pores in plasma 
membranes (168). Additionally, the A oligomer conformation specific antibody A11 binds 
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selectively to the bacterial pore forming protein HL as well as human perforin, indicating shared 
homology and possibly similar mechanisms of pore formation (169). A close link was found for 
both A1-42 and A1-40 between pore formation and cytotoxicity (121). Structural studies indicate 
that these pores may consist of -barrel like structures composed of monomers of A in either 
parallel or antiparallel -sheet (170, 171). Other MD simulations on short A peptides predict 
octameric pores composed of mostly -helical structure (172). 
Nitrosylation of Proteins in AD 
Excess levels of nitric oxide (NO) leading to increased S-nitrosylation (SNO) of proteins 
has been linked to AD (173). NO is produced by nitric oxide synthases (NOS) by the conversion 
of L-arginine to L-citrulline, it easily defuses through plasma membranes allowing it to signal 
neighboring cells. The two NOS relevant to AD are neuronal nitric oxide synthase (nNOS) and 
inducible nitric oxide synthase (iNOS). nNOS is found in neurons and is constitutively active, 
producing low levels of NO. iNOS is constitutively inactive, and when activated, produces high 
levels of NO. Excessive NMDAR activation in AD has been shown to lead to increased levels of 
ROS and NO through nNOS activation (174). Additionally, tangle-bearing neurons in the AD brain 
have been shown to have activated iNOS (175). SNO is a post-translational modification wherein 
a nitric oxide species undergoes a redox reaction with a thiol group on a cysteine (176). Increasing 
SNO of proteins has been linked to multiple neurodegenerative diseases, including AD and 
Parkinson’s disease (144, 145, 161, 177, 178). High levels of SNO proteins has a pro apoptotic 
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affect (179). Transnitrosylation via S-nitrosylating proteins has been identified as a major 
mechanism in the proliferation of SNO proteins throughout cells.  Numerous proteins have been 
identified as having the ability to transnitrosylate other proteins including GAPDH, Cdk5, and 
caspase 3 (176, 180). Cdk5 has been shown to be S-nitrosylated at amino acids 83 and 157 via 
interaction with iNOS (181). SNO-Cdk5 can act in several neurotoxic mechanisms, including 
Transnitrosylation of drp1, activation of the pro apoptotic protein ATM, and phosphorylation and 
loss of function of WAVE1 (180, 182, 183). SNO-Cdk5 has been shown to transnitrosylate Drp1, 
enhancing its GTPase activity leading to altered mitochondrial dynamics (144, 145, 180, 181). 
SNO-GAPDH has been found in AD brains; SNO-GAPDH binds Siah1 and translocates to the 
nucleus where it initiates apoptosis (178, 184, 185). There is also evidence that NO causes cyclin 
dependent kinase 1 (Cdk1) mediated phosphorylation of drp1 enhancing GTPase activity and 
mitochondrial fission (146).  
The nature of AD, namely the long time scale and the difficulty of studying neurons both 
in vivo and in vitro, make pin-pointing of a single mechanism of neuronal death difficult. It is 
likely that some of the aforementioned mechanisms of cytotoxicity are downstream consequences 
of AD and not direct causes; however, it is reasonable to assume that there are multiple often 
interconnected neurotoxic pathways in AD. The lack of a single mechanism to target complicates 
drug development in AD. A stronger understanding of the relationship between A structure and 
toxicity may pave the way the development of early diagnostic tests for AD or novel structure 
based AD drugs. 
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Methodology Literature Search 
The polymorphic nature of the A peptide required detailed review of existing literature. 
To ensure that consistent and reproducible results are obtained, it was necessary to use uniform, 
monomeric solutions of Ain each experiment. Fluorinated alcohols such as 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) are commonly used to induce -helical structure and 
monomerization in A peptides (186, 187). In this work, protein secondary structure was 
determined by CD, literature was therefore reviewed in order to interpret CD spectra (188). 
Review of FTIR 
 Due to the importance of FTIR spectroscopy in this work a thorough review of current 
literature on FTIR was conducted. Infrared spectroscopy is also called vibrational spectroscopy; 
absorption of light is associated with various vibrational modes of chemical groups within a 
molecule. Polychromatic infrared radiation is passed through the sample, when the frequency of 
infrared radiation matches the vibrational frequency of chemical bonds present in the sample, 
absorbance occurs. The absorption frequency of FTIR spectra is displayed in wavenumbers where 
wavenumber W=1/=/c; where  is wavelength,  is temporal frequency of vibration, and c is 
the speed of light. The vibrational frequency  for a diatomic molecule can be approximated using 
equation 1; where the spring constant k is proportional to chemical bond strength. 
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There are many vibrational modes that can be observed in FTIR, but the two most relevant 
to biological study are the amide I and amide II. The amide I vibrational mode is located 1700-
1600 cm-1 and is primarily generated by C=O stretching vibration. These vibrations are coupled 
through covalent bonding, H-bonding, and through space, these couplings shift vibrational 
frequency. Protein secondary structure geometry is highly conserved, making the C=O vibrational 
frequencies of various secondary structures also highly conserved. This allows accurate attribution 
of an FTIR absorbance band to a specific secondary structure. Research was conducted on the 
locations of these amide I secondary structure absorbance peaks in order to interpret experimental 
results (189-191). The peak wavenumber and extinction coefficient of various protein secondary 
structures can be found in chart 1. The amide II is located 1570-1540 cm-1 and is primarily 
composed of NH in-plane bending. The amide II can be utilized to measure the solvent 
accessibility of the protein. Amide hydrogen-deuterium exchange will take place with the addition 
of D2O based buffer. The increased mass of deuterium causes a downshift in absorption and 
corresponding loss of absorbance 1570-1540 cm-1. Proteins in more open or solvent accessible 
conformations will undergo more H-D exchange and thus lose amide II signal intensity more 
quickly than tightly packed proteins. 
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13C Labeling of Proteins 
The 13C-labeling of specific amino acid stretches or entire proteins is a technique to 
investigate protein interaction and examine protein secondary structure in a site-specific manner. 
The amide I absorbance peaks of peptides 13C-labeled is downshifted thus allowing dissection of 
the structure of labeled segments or proteins from unlabeled segments or proteins. This downshift 
was reviewed in order to accurately interpret experimental results (192). The downshifted 
absorbance of a 13C labeled secondary structure can be accurately predicted as shown in equation 
2 by taking the ratio of vibrational frequency of the 13C=16O bond over the 12C=16O and multiplying 
the result by the known absorbance of 12C secondary structures shown in table 1 (Equation 2). For 
example, by taking the known 12C parallel -sheet absorbance at 1636-1630 cm-1 and multiplying 
it by the calculated factor of 0.978, we can predict the absorbance of a 13C parallel -sheet to be 
1600-1594 cm-1. 
√
1
13
+
1
16
1
12
+
1
16
= ~0.978        (2) 
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Table 1. Characteristic amide I wavenumber relative extinction coefficients, and integrated absorbance extinction 
coefficients (B) of various protein secondary structures in D2O, integrated extinction coefficient come from (193). 
Secondary Structure 
Absorbance D2O 
(cm-1) 
Relative Integrated 
Extinction Coefficient 
 
B 
(M-1cm-2) 
-helix 1655-1638 1 5.1 x107 
Parallel -sheet 
(Intramolecular) 
1636-1630 1.37 7.0x107 
Anti-Parallel -sheet 
1636-1630 
(Strong) 
1.37 7.0x107 
 
1680-1670 
(Weak) 
Multiply large 
component by 1.07 
(7% of Strong 
Component) 
Intermolecular (cross-
) -sheet 
1625-1613 1.37 7.0x107 
-turns 1675-1640 1.08 
5.5x107 
Unordered Structure 1648-1640 0.88 
4.5x107 
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CHAPTER THREE: METHODOLOGY 
In this project, we examined A1-42, ApE3-42, and combined samples at both equimolar and 
9:1 (A1-42:ApE3-42) ratios. These molar ratios were utilized because ApE has been observed in 
AD brains at up to 50% of total soluble A load but is commonly present at a lower ratio (13, 20, 
22). However, it has also been demonstrated to have a profound affect even at low molar ratios 
(44, 194). The secondary structures of early oligomers and intermediate structures were 
determined utilizing FTIR and CD. Peptides were first dissolved at concentrations of either 200 or 
50 M in HFIP to break up pre-formed aggregates. Monomer formation of the peptides was 
confirmed by the formation of -helix in HFIP (187). The removal of HFIP was conducted by 
streaming N2 gas over the samples until dried then vacuum desiccating samples for 15 minutes.  
Bulk aqueous buffer was then added to the dried samples. Two different buffers were used 
one at near-physiological ionic concentration and one with low ionic content. The near-
physiological buffer was 50 mM phosphate buffer + 50 mM NaCl pH 7.2 (pD 6.8 for FTIR samples 
in D2O buffer) and the buffer of low ionic content was 10 mM phosphate pH 7.2 (pD 6.8 for FTIR 
samples in D2O buffer). Buffer was added to produce a final peptide concentration of 50 M. The 
ApE3-42 is missing 3 N-terminal charges compared to the unmodified A. It is likely these charges 
form ionic bonds stabilizing the peptides, increasing ionic pressure will weaken these bonds and 
can cause changes in structure distribution. Examining structural changes of the peptides in both 
conditions provides information on the structure formed by the N-terminus of the peptide. 
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Cytotoxicity Assays 
Cytotoxicity assays were conducted with collaboration with Dr. Lucia Cilenti in the 
laboratory of Dr. Kenneth Teter. To assay the cytotoxicity of A aggregates, PC12 cells were 
grown in RPMI 1640 media, supplemented 10% fetal bovine serum, 50-units/ml penicillin and 50 
μg/ml streptomycin. For MTS viability assays cells were seeded in 96-well plates in 
triplicate/samples at a density of 10,000 cells/well in 100 μL complete medium for 18 hours. 
Following this, 100 μL of fresh medium containing A samples aggregated for 2, 4 and 24 hours 
by stirring at 37 °C in PBS, was added to cells followed by incubation at 37 °C for 28 and 50 hours. 
Cell viability was determined by MTS assay, a cell proliferation assay, to monitor 
methanethiosulfonate tetrazolium reduction as an estimate of cell viability, according to the 
manufacturer’s instructions (Promega). In the assay, 20μl of MTS tetrazolium substrate solution 
was added to the wells at 28 and 50 hours followed by further incubation at 37 °C for 3 hours, Cell 
viability in each well was assayed by reading the absorbance at 590 nm in a BioTek microplate 
reader Synergy 2. Percentage of cell viability was calculated by subtracting the average of the 
triplicate samples at 490nm absorbance from medium control (no cells/background) from all other 
absorbance values. 
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Membrane Calcium Release 
 The ability of A aggregates to induce the release of calcium from lipid vesicles was 
assayed using Quin-2. 40 M Quin-2 in the presence of 100 nm unilamellar vesicles of 
POPC/POPG/cholesterol (6:3:1) loaded with 30 mM CaCl2 in aqueous buffer pH 7.2. The total 
lipid concentration was 0.5 mM and peptides were added for a final ratio 1:100 peptide:lipid. 
Peptides were added after 2 and 24 hours of aggregation at 37 oC in PBS. Control was conducted 
by addition of PBS followed by complete release of all entrapped Ca2+ via addition of 0.05% Triton 
X-100 which disrupted vesicles.  
FTIR 
All FTIR measurements were taken on a Vector-22 FTIR spectrometer (Bruker Optics, 
Billerica, MA, USA) equipped with a liquid N2 cooled Hg-Cd-Te detector with a 2 cm
-1 resolution. 
All buffers were made utilizing D2O, and not H2O, to avoid artifacts caused by absorption of H2O 
in the amide I region. Transmission spectra collected for all samples were taken by co-adding 
either 500 or 1000 consecutive scans. Peptides dissolved in HFIP were first deposited on the CaF2 
FTIR window, and then desiccated for 15 minutes to remove HFIP. Transmission spectra were 
then taken and absorption was calculated using a reference transmission spectra. After the 
collection of a dried sample, buffer was added along with a second CaF2 window. Separating CaF2 
windows was a 50 m Teflon spacer. Transmission spectra were then taken consecutively and 
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absorbance was calculated using a buffer reference. Data for both uniformly and segmentally 13C 
labelled peptides was obtained similarly along with data for mixed samples. Samples of 
atmospheric vapor was collected separately and used to clean up spectra as necessary. Spectra 
were smoothed using a 13-point Savitzky-Golay linear least squares algorithm and then baselined. 
Absorbance spectra were prepared using OPUS spectroscopy software.  
Curve-Fitting of FTIR Spectra 
 Curve-fitting of FTIR spectra was performed using GRAMS IO spectroscopy software. 
The locations of amide I components were based on negative peaks in the second derivative. 
Curve-fitting was considered acceptable when peak wavenumbers of components were in 
agreement with the second derivatives, the sum of all components reasonably fit the experimental 
spectra, and the peak component widths were within reasonable limits i.e. width at half height of 
less than 40 wavenumbers (190). The relative fraction Fi of either -helix (), -sheet (), -turn 
(t), and other structures, were calculated based on the area of fit peaks using equation 3 where B 
refers to the average integrated extinction coefficient of the described structures as previously 
described (195). 
𝐹𝑖=
𝑎𝑖
𝐵𝑖(
𝑎𝑎
𝐵𝑎
+
𝑎𝛽
𝐵𝛽
+
𝑎𝑡
𝐵𝑡
+
𝑎𝑜𝑡ℎ𝑒𝑟
𝐵𝑜𝑡ℎ𝑒𝑟
)
      (3) 
30 
 
Hydration FTIR 
 To facilitate examination of early peptide intermediates and structural 
transformations peptide transition was delayed by hydrating from gas phase, using D2O vapor and 
not aqueous buffer. This was done using two separate mechanisms. In the first, dried peptides both 
individually and in combination, were hydrated via exposure to ambient humidity. For the second 
a custom apparatus was designed to hydrate peptides inside the FTIR spectrometer via the pumping 
in of D2O laden N2 gas (Figure 1). In this setup two separate hoses of N2 gas was bubbled through 
two flasks of D2O and then piped into the spectrometer. Peptides were prepared from 50 M stocks 
in HFIP as described earlier. To examine the effect of co-incubation peptides were dried on either 
the same side or opposite sides of the CaF2 windows to allow comparison between interacting and 
non-interacting peptides (Figure 1A). 
 
Figure 2. A) Schematic depiction of the experimental set-up. Nitrogen gas is pumped through simmering D2O into the 
sample compartment. Only two of four flasks with D2O are shown for simplicity. Two sample holders are mounted 
vertically, at 90 degrees, one with two peptides at opposite sides of a CaF2 window and one with both peptides blended 
at one side. Consecutive FTIR spectra of the two samples are measured while the sample holder frame is turned back 
and forth by 90 degrees. Red arrows represent the infrared light. B) Photograph of the FTIR spectrometer during an 
actual experiment. The inset (middle bottom) provides a glimpse into the sample compartment. 
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Circular Dichroism 
CD measurements of A in HFIP were taken in either a 0.5 mm cylindrical cuvette or a 
4x4 mm rectangular quartz cuvette. Measurements were conducted on a Jasco J-810 
spectropolarimeter (Tokyo, Japan). For measurements in aqueous buffer HFIP was removed with 
N2 gas followed by desiccation for 30 minutes, prior to the addition of buffer. After the addition 
of 50 mM phosphate + 50 mM NaCl pH 7.2 aqueous buffer samples were incubated at 37oC while 
stirring and a final protein concentration of 50 M. CD measurements were taken between 330-
180 nm. After collection spectra were smoothed in Spectra Manager software using 9 point 
Savitzky-Golay linear least squares algorithm. 
TEM 
TEM measurements were performed with the assistance of the lab of Dr. Bo Chen 
(University of Central Florida, Orlando, FL, USA). Peptides were dissolved in HFIP, dried, and 
buffer was added as previously described. Samples were then stirred at 37oC for 24 hours. For 
measurements 5 mL of sample was placed on graphene coated grids. After five minutes excess 
buffer was removed. Samples were then washed twice with diH2O and negatively stained with 3% 
uranyl acetate. Samples were measured on a JEOL TEM-1011 (Tokyo, Japan) at 80kV. Samples 
were examined at 2,4,12, and 24 hours to examine aggregation and morphology. 
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CHAPTER FOUR: RESULTS 
Pyroglutamylated Amyloid- Peptide Reverses Cross -Sheets by a Prion-Like Mechanism 
Circular Dichroism of A Proteins 
We first sought to clear up disagreement in the literature about the -sheet propensity of 
ApE compared to the unmodified peptide. Some groups reported ApE to have a lower -sheet 
propensity than the unmodified peptide while others have proposed the opposite. To clear up this 
contradiction we examined the structural changes of ApE and unmodified A throughout 
aggregation using CD. 
To prepare monomeric samples A was first dissolved in HFIP to break up pre-formed 
aggregates. HFIP disrupts -sheet formation and promotes formation of -helical structure (187). 
CD spectra of peptides dissolved in HFIP at 50 M show a minima at 203 with a shoulder at 220 
nm (Figure 3A). This is indicative of -helix and disordered structures. This is in agreement with 
previous data of A proteins in HFIP and implies a monomeric solution. Spectra taken after the 
removal of HFIP indicate that the peptides are -helical shown by two minima located at 208-209 
nm and 221-224 nm (Figure 3B). Interestingly, the ApE3-42 has a significantly reduced 208/222 
ratio, indicating a more flexible or disordered -helix (196). 
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Figure 3. (A) CD spectra of A1-42 (red), ApE3-42 (blue) their 9:1 (teal) and, equimolar (green) ratios in HFIP at a 
peptide concentration of 50 M. (B) CD spectra of the same peptides following HFIP removal via N2 drying and 
vacuum desiccation. 
Following desiccation aqueous buffer was added to the sample for a final peptide 
concentration of 50 M and samples were constantly stirred at 37°C. In physiological buffer 
conditions A1-42 rapidly forms -sheet as shown by the broad minima at 216-219 nm present 10 
minutes after the addition of buffer (Figure 4A). After 16 hours this minima had red shifted to 220 
nm possibly indicating decreased accessibility of the solvent due to tight packing during 
aggregation, such as in fibrillogenesis. Alternatively, ApE3-42 spectra at 10 minutes has a wide 
minima from 208-230 nm likely indicating presence of -helical, -sheet, and turn structures 
(Figure 4B). After 2 hours this minima has shrunk to 212-223 nm indicating the presence of a 
combination of both -helical and -sheet structures. After 24 hours of aggregation a single 
minima at 219 nm is present indicating a majority -sheet structure. This demonstrates that A1-42 
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readily forms -sheets while ApE3-42 has a higher propensity to retain -helical structure and 
delayed formation of -sheet. 
The 9:1 (A1-42:ApE3-42) combination after 10 minutes of aggregation contains a wide 
minima at 217 nm consistent with the presence of mostly -sheet (Figure 4C). Throughout 
aggregation this peak grows in intensity, after 24 hours a single minima at 219 nm is present 
indicating the likely presence of fibrils. For the first hour the equimolar combination contains 
mixed -helix/-sheet content indicated by the wide minima 210-216 at ten minutes and two 
minima at 212 and 222 nm after one hour (188). At 2 hours of aggregation onward a minima 
located at 217 nm indicates presence of mostly -sheet structure. The equimolar combination after 
one hour resembles the ApE3-42 in that it retains -helical structure and resists converting fully to 
-sheet structure (Figure 4D). 
This data indicates that ApE has a lower -sheet propensity than unmodified A. Data 
from combined samples indicates that ApE3-42 alters A1-42 structural transition. Alone, A1-42 
rapidly forms fully -sheet aggregates, while forming mixed -helix/-sheet aggregates in 
equimolar combination with ApE3-42.  
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Figure 4. CD spectra of A1-42 (A), ApE3-42 (B), their 9:1 (A1-42/ApE3-42) (C) and, equimolar (D) ratios in 50 mM 
phosphate 50 mM NaCl buffer pH 7.2 Spectra are shown 10 minutes (red), 1 hour (green), 2 hours (blue) and, 24 
hours (pink) after addition of buffer. Final peptide concentration was 50 M and aggregation took place at 370C with 
constant stirring. For A1-42 the spectra in pink corresponds to 17h as subsequent time points gave weak signal due to 
evaporation of the sample. Spectra were cut at 210 nm due to weak signal from Cl and peptide absorbance. 
TEM of A Fibrils 
Secondary structure is linked to fibrillogenesis and fibril morphology (134). The structural 
differences between the two peptides therefore indicate a strong possibility of altered 
fibrillogenesis. There are currently disagreements in the literature about the fibrillization kinetics 
of ApE in comparison to the unmodified peptides. To clear this up, fibril formation and 
morphology was examined via TEM. Samples were examined at 2,4,12, and 24 hours of 
aggregation in 50 mM phosphate + 50 mM NaCl buffer pH 7.2. To determine the effect of peptide 
interaction peptides were examined separately as well as in equimolar and 9:1 (A1-42:ApE3-42) 
mixed samples. 
The largest differences between samples was observed after 2 hours of incubation. The 
ApE3-42 sample is dominated by irregularly shaped prefibrillar aggregates with dimensions 
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between 30-100 nm (Figure 5b). The A1-42 sample at 2 hours consists mostly of fibrils with a 
smaller number of pre fibrillar aggregates (Figure 5a). The rapid formation of pre-fibrillar 
aggregates by ApE3-42 may be due to its increased hydrophobicity. Both the 9:1 (Figure 5c) and 
1:1 (Figure 5d) samples resemble the ApE3-42 sample with a large number of pre-fibrillar 
aggregates compared to mature fibrils. At 4 hours fibrils were present in all samples along with 
significant amounts of prefibrillar aggregates (Figure 5e-h). At 12 (Figure 5i-l) and 24 (Figure 5m-
p) hours fibrillogenesis continued and more mature fibrils were found in all samples along with 
decreased levels of prefibrillar aggregates. 
This data demonstrates that the unmodified A undergoes more rapid fibrillogenesis than 
ApE. This data agrees with CD data showing that A1-42 rapidly forms -sheet indicative of fibril 
formation while ApE3-42 and the 1:1 combination retain a prominent -helical component. The 
increased levels of prefibrillar aggregates compared to fibrils at two hours in mixed samples 
demonstrates that ApE3-42 has a profound effect on fibrillogenesis particularly in the early stages 
of aggregation (135). The lack of fibrils in the 9:1 sample is evidence of the strong effect ApE3-42 
can exert even at low molar ratios. Interestingly, in the 9:1 sample there was no delay in -sheet 
formation coinciding with the delay in fibrillogenesis. This indicates that the delay in 
fibrillogenesis found in mixed samples may not simply be due to inhibition of -sheet formation. 
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Figure 5. TEM images of Aβ1−42 (a, e, i, m), AβpE3-42 (b, f, j, n), AβpE3-42/Aβ1−42 = 1:9 (c, g, k, o), and AβpE3-42/Aβ1−42 = 
1:1 (d, h, l, p) incubated in aqueous buffer of 50 mM NaCl + 50 mM Na,K-phosphate (pH 7.2) for 2 h (a−d), 4 h (e−h), 
12 h (i−l), and 24 h (m−p) at 37 °C with constant stirring. The horizontal bar in each panel equals 100 nm. 
FTIR of Amyloid Beta Peptides 
We next sought to examine the structure of these peptides in greater detail utilizing FTIR. 
FTIR gives greater structural resolution than CD allowing, for instance, the determination of 
whether the protein is forming intramolecular or intermolecular -sheet. Formation of 
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intramolecular -sheet and not intermolecular -sheet, as found in fibrils, may explain the delay 
of fibrillogenesis despite rapid -sheet conversion of the 9:1 sample. Utilizing uniformly 13C-
labeled A1-42 allowing the assignment of structural components to individual peptides in mixed 
samples. This allowed the probing of structural changes in both peptides caused by interaction 
with one another. 
Peptides were first examined individually by depositing 40 L of a 200 M solution of A 
in HFIP to the CaF2 FTIR window. HFIP was then removed via vacuum desiccation for 15 minutes 
and FTIR measurements were taken of the proteins in a dried state. The 13CA1-42 spectra contains 
a major peak at 1588 cm-1 indicating the presence of intermolecular -sheet structure (Figure 6). 
It also contains a broad component likely corresponding to -turns (~1660 cm-1) and an 
insignificant -helical component (1617 cm-1). The ApE3-42 is forming intramolecular -sheet that 
is possibly anti-parallel as indicated by the peak at 1634 cm-1 and small shelf present at 1695 cm-
1(189) (Figure 6). The presence of structures other than -helix in the dry samples indicates that 
the peptides can undergo structural transitions in the absence of aqueous buffer due to atmospheric 
humidity. 
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Figure 6. FTIR spectra of AβpE3-42 (Light Blue) and uniformly 13Clabeled Aβ1−42 (Green) dried from a 200 μM HFIP 
solution on a CaF2 Window. The amide I area of spectra was normalized. 
The observation that atmospheric humidity was sufficient to induce structural changes gave 
us the idea to examine the effect of ApE3-42 on the early stages of A1-42 aggregation utilizing 
atmospheric humidity. Using humidity we examined early transitions of both equimolar and 9:1 
molar combination samples. Samples in HFIP were added to FTIR windows and HFIP was 
removed by desiccation as described earlier. Samples were then exposed to atmospheric humidity 
for either 10 or 20 minutes and FTIR spectra was taken. Individual peptides were also measured 
after 15 minutes of atmospheric humidification and their weighted sum was compared to combined 
samples. The absorption of atmospheric humidity is demonstrated by a corresponding increase in 
absorbance in the H2O band located 3450-3150 cm
-1 (Figure 7A). In the 9:1 molar ratio, as the 
sample is hydrated the structure transitions from -helix (1617 cm-1) to -sheet (1592 cm-1) 
evidenced by an increased 1592/1617 ratio in the 20 minute sample when compared to the 10 
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minute sample (Figure 7B). The broad peak ~1655 cm-1 likely corresponds to A1-42 turn structure 
as well as ApE3-42 turn and -helical structures. The lower absorbance by the weighted sum of 
individual peptides at 1617 cm-1 indicates less -helical content in the A1-42 in the absence of 
ApE3-42. This is evidence that ApE3-42 restricts -helix to -sheet transition of the A1-42. The 
differences in the equimolar samples are even more pronounced. The weighted sum at 15 minutes 
contains prominent peaks at 1588 and 1634 cm-1 likely corresponding to intermolecular -sheet of 
the A1-42 and intramolecular -sheet of the ApE3-42 respectively (Figure 7C). The broad shelf 
~1660 cm-1 is likely composed of A1-42 turns as well as ApE3-42 -helix and turn structures. 
Experimental spectra at 10 minutes show a decrease in -helix-to--sheet transition of ApE3-42 
evidenced by a decrease in 1634/1658 ratio when compared to the weighted sum. The A1-42 -
helix-to--sheet transition is also inhibited at 10 minutes as demonstrated by an increase in peak 
height at 1617 cm-1 and a decrease in the corresponding -sheet height present at 1595 cm-1 in the 
experimental and 1588 cm-1 in weighted sum spectra’s respectively. The peak at 1595 cm-1 likely 
corresponds to intra- not intermolecular -sheet structure. At 20 minutes the differences are even 
more pronounced. The major peak at 1658 cm-1 indicates that ApE3-42 is mostly -helical. Minor 
shelves located at 1617 and 1595 cm-1 correspond to A1-42 -helix and intramolecular-sheet 
respectively. The similar intensities at 1617 cm-1 for both 10 and 20 minutes indicate a lack of 
transition from -helix of the A1-42.  
This data indicates that at 10% of total peptide ApE3-42 delays formation of cross- 
structure of A1-42. At 50% the effect is even more pronounced with Ape3-42 inhibiting 
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intermolecular -sheet formation of A1-42 in favor of intramolecular at 10 minutes, and inhibiting 
any -sheet formation at 20 minutes. Additionally, the ApE3-42 forms more -helix than -sheet 
when in combination with A1-42, this indicates that A1-42 inhibits ApE3-42 -to- conversion. 
 
Figure 7. FTIR spectra of AβpE3-42 and uniformly 13CAβ1−42 at 1:9 molar ratio (A and B) and 1:1 molar ratio (C). Green 
and Red lines are experimental spectra of a sample prepared in HFIP, followed by solvent removal by desiccation and 
exposure to atmosphere for 10 and 20 min, respectively. The Blue is the weighted sum of the spectra of each peptide 
measured individually, exposed to the atmosphere for 15 min. Construction of the weighted sum spectra is described 
under Figure 4. Panel B is a zoom-in into the amide I/II region of spectra shown in panel A. 
We next examined structural differences between the peptides in aqueous buffer, 10 mM 
phosphate pD 6.8 buffer was added to samples following measurement of the dried peptides and 
spectra were taken every ten minutes. After the addition of buffer both peptides formed 
predominantly intermolecular -sheet structure evidenced by a major peak at 1628 cm-1 for the 
ApE3-42 (Figure 8B)and 1585 cm-1 for the 13CA1-42 (Figure 8A). Additionally, the ApE3-42 had 
significant turn and -helical components as evidenced by the secondary peak ~1673 cm-1. The 
small peak at 1673 cm-1 in the 13CA1-42 sample is likely due to trifluoroacetic acid (TFA) which 
is commonly found in synthesized peptides. 
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Examination of the Amide II components of spectra gives additional insight into protein 
structure. Use of a D2O based buffer causes hydrogen-deuterium (H-D) exchange and a 
corresponding loss of amide II intensity around 1540 cm-1(190, 197). Examination of the Amide 
II of both peptides for two hours shows a loss of amide II intensity for the ApE3-42 and no loss of 
intensity for A1-42 (Figure 8). The lack of a drop in Amide II intensity indicates that the amide 
hydrogens are being shielded from the buffer via formation of a more compact tertiary structure 
and/or a less flexible secondary structure, as is found in mature fibrils. 
 
Figure 8. FTIR spectra of A
1-42
 (A) and A
pE3-42
 (B) in 10 mM Na,K-phosphate in D2O, pD 7.2. Change from Blue 
to Red corresponds to time of exposure of the peptides to the buffer for 10, 30, 50, 70, 90, and 120 min. 
Next, we examined spectra of mixed 13CA1-42 and ApE3-42 samples to determine structural 
effects of co-incubation. After 2 hours of incubation in 10 mM phosphate pD 6.8 experimental 
spectra were compared to the weighted sum of individual spectra. When compared to the weighted 
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sums of individual spectra the A1-42 -sheet peak (1585 cm-1) is upshifted by 3 and 10 cm-1 in the 
9:1 (Figure 9A) and 1:1 samples (Figure 9B) respectively. The latter shift to 1595 cm-1 implies 
formation of intra- not inter-molecular -sheet. The ApE3-42 -sheet peak (1626-1628 cm-1) was 
downshifted compared to individual peptides by 4 cm-1 in the equimolar combination. These shifts 
are likely due to 13C:12C coupling and imply strong interactions between the two peptides. It is 
thus clear that A1-42 and ApE3-42 form hybrid oligomers composed mostly of -sheets. Curiously, 
in the 9:1 sample ApE3-42 is upshifted 10 cm-1 from 1626 to 1636 cm-1 (Figure 4A). This peak can 
most likely be attributed to intramolecular not intermolecular -sheet which is characteristic of 
mature fibrils. This implies that when incubated with A1-42 at low molar ratio ApE3-42 
fibrillogenesis may be inhibited. 
 
Figure 9. FTIR spectra of AβpE3-42 and 13CAβ1−42 combined at 1:9 (A) and 1:1 (B) molar ratios, incubated in a D2O-
based phosphate buffer (pD 7.2) for 2 h, at a total peptide concentration of 100 μM. Red and Blue lines are the 
experimental spectra obtained on the two peptides combined in one sample and the weighted sums of individual 
spectra, respectively. The weighted sums were obtained as A = Σf iAi, where fi is the molar fraction and Ai is the 
absorbance spectrum of each individual peptide measured separately. 
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This project gave insight into the structural transitions of A1-42 and ApE3-42 as well as the 
structure of early oligomers. It was found that A1-42 has a greater -sheet forming propensity than 
ApE3-42. Additionally, in hybrid samples ApE3-42 delays or even reverses formation of cross -
sheet by A1-42. The effect of ApE on fibrillogenesis was demonstrated via TEM data showing 
mature fibrils in the A1-42 samples while the ApE3-42 sample contains mostly prefibrillar 
aggregates. The hybrid samples resemble the ApE3-42 indicating a strong effect on fibrillogenesis. 
FTIR data indicates that ApE inhibits formation of A1-42 intermolecular -sheet which makes 
up fibrils. This inhibition of -sheet formation and thus fibrillization of A1-42 by ApE3-42 is 
interesting and a possible mechanism of increased toxicity. Delay or inhibition of fibrillization 
likely leads to a corresponding increase in the population of soluble oligomers or drive the 
formation of off-pathway aggregates of increased toxicity. However, the lack of -helical structure 
in FTIR of dried peptides indicates structural transitions had occurred before buffer addition, 
calling these results into question. In addition the peptides were examined in buffer with 
significantly less ionic content that in physiological conditions. Moving forward with this project, 
we sought to examine the early oligomer structure of ApE and unmodified A as well as address 
these two concerns. 
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Isotope-Edited FTIR Reveals Distinct Structural Features of Unmodified and Pyroglutamylated 
Amyloid- Peptides During oligomerization 
 Next, we sought to characterize the structure of oligomers formed by A1-42 and ApE3-42 
as well as hybrid oligomers (198). In mixed samples it was observed that ApE3-42 inhibits cross -
sheet formation and fibrillogenesis of A1-42. A oligomers are heavily implicated in AD but little 
is known of their structures, so we wished to better characterize the structure of the oligomers 
formed by these peptides. Here we utilized peptides 13C- and 15N-labeled at specific stretches, 
these labels allow site specific determination of secondary structure as well as provide tertiary and 
quaternary structural information. Labeled proteins were examined in both 10 mM phosphate 
buffer pD 6.8 as well as in near-physiological 50 mM phosphate + 50 mM NaCl buffer pD 6.8. 
These data provide structural constraints for the modeling of early monomers and oligomers of 
A. Using these constraints, we propose a possible structure for monomeric A as well as likely 
mechanisms of early oligomerization. 
Isotope Labeling of Peptides 
In order to gain site-specific secondary structural information we utilized peptides that had 
been 13C and 15N labelled at specific locations. Peptides were generated with labels in two 
locations, K16L17V18 and V36G37G38V39. Solution NMR studies of the A containing APP segment 
reconstituted in micelles show an -helix starting at K16L17V18 and a bend involving V36G37G38V39 
near the C-terminus. After cleavage of A from the membrane this -helical structure undergoes 
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structural transitions eventually forming the cross -sheet structure found in fibrils. The 13C 
labelling of these segments causes a downshift in the amide I spectra allowing site-specific 
secondary structural information. In addition by examining the carbon coupling of these labelled 
segments we are able to gain quaternary structural information. If two labelled segments are in 
close proximity as is found in the in-register parallel -sheet characteristic of fibrils they will 
undergo 13C:13C coupling and a further downshift of absorbance will occur. If the labelled 
segments are not in close proximity to one another they will instead undergo 13C:12C coupling and 
a slight upshift of their associated absorbance peak will occur. 
FTIR of Dried Proteins 
Prior to the addition of buffer, measurements were taken of the peptides dried from HFIP. 
Peptides in HFIP were first deposited on the CaF2 window and then HFIP was removed via 
desiccation. It was previously observed that atmospheric humidity is sufficient to induce structural 
changes. In order to obtain reliable data, HFIP is used break up pre-formed aggregates and 
monomerize A. Previously, in CD of proteins dried from HFIP we observed -helical structures. 
We sought to capture this -helical structure in FTIR to ensure consistent A populations prior to 
the addition of bulk aqueous buffer. To ensure this, we lowered the protein concentration to 50 
M in HFIP, as high concentrations have been shown to induce aggregation (199). When peptides 
were dried from HFIP, using the lower concentration and keeping care not to keep samples in the 
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humid lab air for long, both ApE3-42 and A1-42 as well as their equimolar combination form mostly 
-helical structure, evidenced by the absorption peak at 1658-1662 cm-1 (Figure 10A). This 
absorbance is higher than is found in more stable -helices (1647-1657 cm-1) and suggests that the 
-helix formed by A peptides is more flexible. This more flexible -helix agrees with previous 
data of the A1-42 segment of the APP (98, 99). To accurately place and quantify the additional 
peak generated by the labeled residues the second derivative of dried spectra was calculated 
(Figure 10B). Peak fitting was then performed to quantify the additional peaks (Table 2) (Appendix 
A). For K16L17V18 labeled peptides an additional peak at 1624-1628 cm-1 is found corresponding 
to the labelled segment. This area is consistent with -helix composed of 1-4 13C labeled residues 
(190). The reason for the less-than-expected downshift is i-i+4 H-bonding with unlabeled peptides. 
In peptides labeled at V36G37G38V39 the dried spectra contains an additional peak at 1596-1602 
cm-1. This peak is located at a lower wavenumber and is lower intensity than would be expected 
from a 13C -helix comprising 4/42 or 4/40 suggesting that the C-terminus of the protein is 
disordered and the peptides are acting as isolated oscillators (Table 2) (190). This data indicates 
that in a dry state the peptides adopt a flexible -helical structure involving K16L17V18 while the 
V36G37G38V39 sequence close to the C-terminus is unordered. This agrees with previous 
observations of A containing segments of the APP reconstituted in micelles as well as MD 
simulations (98, 99, 200). This demonstrates that these dried peptides resemble A prior to 
membrane release into an aqueous environment, making them a biologically relevant starting 
material for the study of A structural changes and aggregation. 
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Figure 10. (A) FTIR spectra of dry peptides in the amide I regions. Spectra for unlabeled and isotopically labeled A1-
42 and ApE3-42 peptides and their 1:1 combinations are presented. Gray dotted lines correspond to ApE3-42, and solid 
black lines correspond either to Ab1-42 or to combined samples, as indicated. KLV or VGGV imply the peptides have 
been labeled at K16L17V18 or V36G37G38V39, respectively. In KLV/VGGV or VGGV/KLV samples, the first stretch 
applies to Aβ1-42 and the second to AβpE3-42. (B) Second derivatives of the corresponding FTIR spectra. 
Table 2. Relative amide I content of the 13C labeled peaks in peptides dried from HFIP. In the columns with two 
different labels the first one corresponds to A1-42 and the second to ApE3-42. 
 A1-42 ApE3-42 1 to 1 KLV/VGGV VGGV/KLV Total 
KLV 12.3% 15.5% 13.3% 13.0% 12.6% 13.3±1.3% 
VGGV 8.2% 12.4% 8.9% 2.2% 7.4% 7.8±3.7% 
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FTIR of Unlabeled Peptides 
After measurement of dried peptides aqueous buffer was added and measurements were 
taken consecutively (1000 scans takes ~10 minutes). After 10 minutes in 10 mM Phosphate buffer 
pD 6.8 the peptides and their equimolar combination form type 1 -turn and intramolecular -
sheet as evidenced by the major peaks at 1673 and 1635-1630 cm-1 respectively (Figure 11D) 
(190). Consistent with previous observations, the peptides retain some -helical structure 
evidenced by absorption ~1660 cm-1. Peptides in near-physiological buffer conditions have similar 
absorption peaks and shape indicating formation of type 1 -turn, -helix, and intramolecular -
sheet (Figure 11A). After 2 hours the location of the -sheet was downshifted 2-5 cm-1 likely due 
to H-D exchange. This indicates that the peptides are in a loose conformation allowing solvent 
access to the majority of peptides residues (Figure 11C). The -sheet absorbs 1633-1628 cm-1 
indicating the presence of intramolecular -sheet as intermolecular -sheets absorb at a lower 
wavenumber 1613-1625 cm-1. In near physiological conditions ApE3-42 contains more -helix and 
less -sheet compared to A1-42 indicated by a higher ratio 1660/1630-35 cm-1(Figure 11A-C). In 
low ionic buffer conditions the opposite is true with A1-42 containing more -helix and less -
sheet than ApE3-42 (Figure 11D-F). These differences are evident when examining A1-42 –ApE3-
42 difference spectra. In physiological ionic conditions a negative peak at 1660 cm
-1 and a positive 
peak at 1620 cm-1 indicate more -helix and less -sheet in the ApE3-42 sample compared to the 
A1-42 (Figure 12A). The opposite is seen in low salt buffer with a large negative peak at 1620 cm-
1 and a positive peak at 1660 indicating less -helix and more -sheet in the ApE3-42 (Figure 12C). 
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Taking the difference spectra of the 1:1 and the weighted sums of the individual peptides show 
differences caused by peptide interactions. If there were no changes due to peptide interaction this 
line would be flat. In physiological ionic conditions difference spectra has positive components at 
1670 and 1653 cm-1 and a negative component at 1625 cm-1, indicating peptide interaction 
enhances formation of -turn and -helix and inhibits -sheet formation (Figure 12B). In low salt 
a positive component at 1673 cm-1 and a negative one at 1625 cm-1 are present (Figure 12D). This 
indicates that peptide interaction causes formation of more -turn and less -sheet structure. In 
near-physiological conditions the 1:1 sample more closely resembles the ApE3-42 forming more 
-helix and less -sheet; this agrees with previous data that ApE3-42 strongly influences the 
structure of hybrid samples. In low salt conditions the 1:1 more closely resembles the A1-42 
forming more -turn and less -sheet structure. 
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Figure 11. FTIR spectra of 50 mM A1-42 (Green) ApE3-42 (blue) and their equimolar combination (Red) in 50 mM 
phosphate + 50 mM NaCl pD 7.2 (ABC) and in 10 mM phosphate pD 6.8 (DEF) buffers. Time points shown are 10 
minutes (A,D) 60 minutes (B,E) and 120 minutes (C,F). Total peptide concentration is 50 M 
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Figure 12. Difference FTIR spectra of Aβ1-42 and AβpE3-42 peptides and their equimolar combinations in 50 mM NaCl 
+ 50 mM phosphate buffer (A, B) and 10 mM phosphate buffer (C, D), pD Spectra in A) and C) show the difference 
Aβ1-42 - AβpE3-42, and those in B) and D) show the difference between 1:1 combination and the normalized sum of the 
spectra of the two peptides. Blue, green, and red correspond to the peptide samples incubated in a D2O-based buffer 
for 10, 60 and 120 min, respectively. Total peptide concentration is 50 μM. 
In order to quantitate the relative fractions of secondary structure present peak fitting was 
performed with peaks being placed based on the second derivative of the spectra (Appendix B). 
While peak fitting it was noticed that in 50 mM phosphate + 50 mM NaCl pD 6.8 buffer the 1:1 
-helix was downshifted to ~1653 cm-1. This downshift is likely due to helix stabilization. Peaks 
were assigned to secondary structures based on location of the absorbance peak. Data after 10, 60, 
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and 120 minutes of hydration was averaged (Table 3). In physiological buffer conditions ApE3-42 
contains more -helix and less -sheet than A1-42 while the opposite is true in buffer of less ionic 
content. The 1:1 combination similarly resists -helix-to--sheet conversion. 
This is consistent with our previous observations that ApE3-42 is able to retard -sheet 
formation in hybrid samples. The changing -helical propensity based on ionic conditions is 
evidence that the -helix is located in the N-terminus of the peptides. The -helix of A1-42 can be 
stabilized by ionic interactions at the N-terminus such as D1-K16, E3-K16, D1-R5, R5-E11. Higher 
concentrations of ionic charges will weaken this ionic stabilization. The ApE3-42 is missing three 
N-terminal charges and thus does not form some of these stabilizing ionic interactions. 
Table 3. Secondary structures of A1-42, ApE3-42, and their equimolar combination in 50 mM phosphate 50 mM NaCl 
pD 6.8 (light blue) and 10 mM phosphate pD 6.8 (unshaded) determined by curve fitting of amide 1 spectra. Numbers 
shown are averages taken after 10, 60, and 120 minutes in buffer. Other refers to all other peaks fit and is primarily 
composed of unordered structure. 
 A1-42 ApE3-42 1 to 1 
-helix 
11.0±2.4 18.7±3.2 22.9±3.6 
24.8±5.1 13.6±1.8 16.3±2.1 
-sheet 
50.4±4.6 43.0±4.4 34.5±3.9 
38.7±4.8 48.9±3.6 34.2±3.2 
-turn 
18.1±3.3 20.3±1.7 28.4±2.4 
24.0±2.7 19.8±1.3 27.7±3.6 
other 
20.5±3.9 18.0±2.2 14.2±1.3 
12.5±3.6 17.7±2.6 21.8±2.7 
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FTIR of Labeled Peptides 
 After dry measurement of the labeled peptides buffer was applied and consecutive 
measurements were taken as with the unlabeled peptides. After ten minutes in both buffers the 
spectra for the peptide resembles the unlabeled with major peaks ~1673 cm-1 and between 1637-
1628 cm-1 corresponding to type 1 -turn and intramolecular -sheet respectively (Figure 12). 
Overlaying the K16L17V18 and V36G37G38V39 spectra over the unlabeled spectra discussed 
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previously identifies an additional peak located ~1598-1604 cm-1(Figure 13). This peak can be 
attributed to the 13C labeled amino acids in the peptides. 
 
 
 
Figure 13. FTIR spectra of A1-42 (A,D), ApE3-42 (B,E) and, their 1:1 combination (C,F) after 10 minutes in 50 mM 
phosphate 50 mM NaCl pD 7.2 (A,B,C) and 10 mM phosphate pD 7.2 (D,E,F) buffers. Colors correspond to unlabeled 
peptide (Red) as well as proteins 13C- and 15N- labeled at K16L17V18 (Blue) and V36G37G38V39 (green). Total peptide 
concentration is 50 M. 
 When labeled at K16L17V18 in 50 mM phosphate + 50 mM NaCl pD 6.8 buffer the ApE3-
42 retains more -helix than A1-42 as with the unlabeled peptides (Figure 14 A-C). The A1-42 
instead forms more type 1 -turn structure demonstrated by the larger absorbance at 1673 cm-1. 
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Additionally, the -sheet absorbance of the A1-42 is downshifted 3-5 wavenumbers in comparison 
to the ApE3-42 indicating faster formation of -sheet compared to the ApE3-42. The 1:1 
combination -sheet peak absorbs ~1633cm-1 between A1-42 and ApE3-42. This agrees with our 
previous observations that ApE3-42 has lower -sheet propensity than A1-42 and could retard -
sheet formation of the A1-42 in hybrid samples. When labeled at V36G37G38V39 the ApE3-42 
contained more -turn and less -sheet structure than A1-42 indicated by peak heights at 1673 and 
~1635 cm-1 respectively (Figure 14 D-F). As with the K16L17V18 labeled proteins the -sheet peak 
of A1-42 is at lower frequencies than ApE3-42 indicating faster -sheet formation. 
57 
 
 
Figure 14. FTIR spectra of A1-42 (green), ApE3-42 (blue) and, their equimolar (red) combinations after 10 (A,D) 60 
(B,E) and, 120 (C,F) minutes in 50 mM phosphate 50 mM NaCl pD 7.2 buffer. Peptides are 13C- and 15N-labeled at 
K16L17V18 (A,B,C) and V36G37G38V39 (D,E,F). Total peptide concentration is 50 M. 
 When 10 mM phosphate pD 6.8 buffer was added to the peptides the A1-42 formed a higher 
fraction of -turn structure indicated by the peak at 1673cm-1 (Figure 15). Additionally, in the 
K16L17V18 labeled peptides the -sheet peak wavenumber of the ApE3-42 is shifted several 
wavenumbers lower than A1-42 indicating faster -sheet formation by the ApE3-42 (Figure 15A-
C). The 1:1 -sheet is again located between the A1-42 and ApE3-42 -sheet wavenumbers 
indicating that A1-42 retards -sheet formation in the hybrid sample. This agrees with our previous 
data that ApE3-42 has a lower -sheet propensity than the A1-42 and can delay -sheet formation 
in hybrid samples in physiological buffer conditions while the opposite is true in buffer of low 
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ionic content
 
Figure 15. FTIR spectra of A1-42 (green), ApE3-42 (blue) and, their equimolar (red) combinations after 10 (A,D) 60 
(B,E) and, 120 (C,F) minutes in 10 mM phosphate pD 7.2 buffer. Peptides are 13C- and 15N-labeled at K16L17V18 
(A,B,C) and V36G37G38V39 (D,E,F). Total peptide concentration is 50 M. 
 To facilitate placement of the labeled peak the second derivative was calculated, 
examination of the second derivative show a peak that can be assigned to the labeled segment 
~1603-1598 cm-1 (Figure 16). To further quantify this peak as well as to examine secondary 
structure distribution peak fitting was conducted for spectra taken 10, 60, and 120 minutes after 
buffer addition (Appendix C). Taking into account our observed intramolecular -sheet peaks of 
1637-1628 cm-1 we can predict 13C-labeled -sheets to absorb 1601-1592 cm-1 therefore we can 
reliably say that the labeled segment is forming intramolecular -sheet. As discussed earlier, in 
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samples containing both 13C- and12C-labeled samples the 13C-labeled residues can undergo 
vibrational coupling with either 13C or 12C-labeled residues depending on whichever is in close 
proximity. This coupling changes vibrational frequency with 13C:13C coupling causing a downshift 
and 13C:12C coupling causing an upshift in absorbance wavenumber. Taken with our previous 
calculation we can reasonably assign an absorbance 1603-1599 to 13C-labeled -sheets undergoing 
13C:12C-coupling and the absorbance 1596-1592 to 13C-labeled -sheets undergoing 13C:13C-
coupling. Therefore, based on the location of the labeled peak in the second derivative we can 
reasonably conclude that in these samples in any combination neither K16L17V18 nor V36G37G38V39 
segments are adjacent to themselves or one another.  
 
Figure 16.  Second derivative of FTIR spectra taken 10 minutes after the addition of A) 50 mM phosphate + 50 mM 
NaCl pD 6.8 and B) 10 mM Phosphate buffer pD 6.8. For spectra labeled KLV/VGGV or VGGV/KLV the first 
corresponds to A1-42 and the second to ApE3-42. 
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A Modeling 
 Although FTIR data generally does not give tertiary or quaternary structural information 
site-specific 13C-labeling gave site-specific structural information. This information along with the 
other data collected here gives structural constraints useful in the modeling of early A oligomers 
and oligomerization. First, in aqueous buffer both A1-42 and ApE3-42 forms a mixture of primarily 
intramolecular--sheet with lesser amounts of, -helix, -turn, and unordered structures. This -
helix can be placed at the N-terminus based on data collected in buffers with two different ionic 
contents indicating that ApE3-42 has a higher -helix propensity than A1-42 in physiological 
conditions while the opposite is true in buffer with low ionic content. Second, the segments 
K16L17V18 and V36G37G38V39 both form intramolecular -sheet. Third these segments are 
undergoing 13C:12C coupling meaning they are not adjacent to one another. The final constraint is 
based on the small size of these peptides as well as the significant fraction of -helix this makes 
formation of parallel intramolecular -sheets impossible. Based on these constraints we propose 
that the monomeric A is forming a -hairpin with two -strands connected by turn structure 
downstream of K16L17V18 with an N-terminal -helix (Figure 16). The turn segment is likely 
stabilized by a salt bridge between D23 and K28 as predicted in other studies (201).The presence of 
-helix with majority -sheet has been previously observed in A oligomers which display more 
toxicity to cultured PC12 cells compared to mature fibrils which contain no -helical component 
(115). 
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Figure 17. The amino acid sequence of A1-42 arranged in a structure involving a b-hairpin stabilized by D23-K28 ionic 
bridge, and an N-terminal stretch that may assume a-helical conformation. The isotopically labeled amino acids are 
shaded. Underneath is a ribbon model for Ab monomer, composed of a -hairpin and an N-terminal -helix. The 
segments K16L17V18 and V36G37G38V39 are both involved in the b-hairpin and are marked by dark blue colors. 
 These data also give us hints as to how these early monomers aggregate. The lack of 13C:13C 
coupling exclude the possibility of parallel in-register stacking with the aggregation axis 
perpendicular to hairpin plane as found in mature fibrils (Figure 17A). Stacking in an anti-parallel 
arrangement would also cause 13C:13C coupling and can thus be ruled out (Figure 17B). Next we 
examined oligomerization through interactions between the C-termini or N-termini of neighboring 
hairpins. The lack of intermolecular -sheet signal indicates that this interaction is through non-H 
bonding possibly hydrophobic or ionic. Aggregation in this manner in either a parallel (Figure 
17C) or antiparallel (Figure 17D) orientation would again lead to 13C:13C coupling and therefore 
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can be confidently ruled out. We then examined dimerization through non-H bonding between the 
C-termini of one hairpin strand with the N-terminus of a neighboring hairpin in either a parallel 
(Figure 17E) or antiparallel (Figure 17F) manner. In this arrangement there would not be any 
13C:13C coupling matching our experimental observations and is thus not ruled out. This stacking 
could take place with the -strands laterally or in a vertical manner reminiscent of steric zippers. 
This vertical stacking could take place alternatively between strands (Figure 17E) or alternating 
between entire hairpins (Figure 17F).  
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Figure 18. Schematic models for A oligomerization through interactions between the core - hairpin structures. Two 
arrows in each molecule represent two -strands, connected by a loop or turn. The monomers are colored gray and 
pink, and the isotopically labeled segments are indicated by darker color. In all cases, the structures are stabilized by 
intramolecular H-bonding and intermolecular non-H-bonding contacts, i.e. ionic and/or hydrophobic interactions. The 
plane of the picture is parallel to the hairpin plane. In A,B the aggregation axis is perpendicular, and in C-F it is 
coplanar to the picture plane. 
 Here we conducted FTIR on peptides 13C-labeled at specific segments in order to obtain 
site-specific structural information for A1-42, ApE3-42, and their equimolar combinations. Using 
this information as well as information obtained in two buffers with distinct ionic content allow us 
to propose a model for an early monomer composed of a -hairpin with an N-terminal -helix. 
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Additionally, we propose that these monomers aggregate through non-H-bonding interactions 
between the N-terminus of one hairpin and the C-terminus of another. These oligomers are 
structurally distinct form mature fibrils and are formed via a different mechanism of aggregation. 
The consistency of this data throughout repeated experiments, in spite of the polymorphic nature 
of these proteins, lends credibility to these results. 
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Mutual inhibition of fibrillogenesis by A peptides 
 Next, we sought to characterize the transitions and intermediate structures during oligomer 
formation. The toxic A species is thought to be created sometime during the transition from the 
-helical monomer to the mature cross-fibrils. However, it is unknown whether these oligomers 
are formed as intermediates during fibrillogenesis or are formed via alternative pathways. We 
sought to answer this question by examining the -to- transition of the peptides. To accomplish 
this we used a novel approach, hydration from gas phase, (see methods) based on our previous use 
of atmospheric humidity to induce structural changes in A (Figure 6). 
Individual Peptides 
 Prior to examining hybrid samples we first characterized the behavior of individual 
peptides. After desiccating the proteins onto the windows as described earlier, spectra of the dried 
peptide was collected. These spectra indicate that both 13CA1-42 and ApE3-42 are forming 
primarily -helical structure shown by peaks at 1616 and 1657 cm-1 respectively (Figure 18). In 
the 13CA1-42 spectra a shelf present ~1590 indicates presence of a small amount of -sheet and 
the peak ~1673 cm-1 likely corresponds to residual TFA from peptide synthesis. 
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Figure 19. FTIR spectra of 50 M ApE3-42 (red) and 13CA1-42 (blue) in HFIP added to FTIR windows followed by 
HFIP removal by vacuum desiccation. 
 Following measurement of dried peptides structural transitions were initiated by beginning 
the flow of D2O laden N2 gas into the sample chamber. The buildup of D2O within the chamber is 
indicated by increasing intensity of spectral features generated by D2O stretching ~2500 (Figure 
20). This data indicated that D2O saturation level reached one third of maximum after 5 minutes 
and then slowly rose until maximum saturation is reached approximately 3 hours later. After the 
onset of D2O hydration the peak associated with the 
13CA1-42 -helix rapidly diminished while a 
peak corresponding to -sheet ~1590 cm-1 quickly grew indicating a rapid initial rate of -helix-
to--sheet transition (Figure 21A). The peak ~1673 cm-1 is unchanged throughout hydration and 
can be attributed to TFA. Hydration of the ApE3-42 caused a decrease in -helix and a 
corresponding increase in -sheet content indicated by growth of a peak at 1633 cm-1 (Figure 21B). 
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Over time, the reduction in -helical intensity revealed an additional peak at 1673 cm-1 which we 
have previously attributed to type 1 -turns. Additionally, the A1-42 retained an amide II 
absorbance while the ApE3-42 amide II was fully deuterated, as previously observed. This -to- 
transition is easily observed by looking at the second derivative of the initial spectra and one after 
five hours of gas phase hydration (Figure 21C,D). Examination of second derivatives reveal a 
component at 1613 cm-1 in 13CA1-42, this peak indicates retention of -helical structure (Figure 
21C). The downshift in wavenumber is likely due to amide dueteration throughout hydration. A 
small component ~1660 cm-1 in the ApE likely corresponds to some residual -helix as well 
(Figure 21D). 
 
68 
 
 
Figure 20. FTIR Spectra of ApE3-42 sample in D2O absorbance region at various times of continuous injection of D2O-
saturated nitrogen. The intensity of D2O asymmetric stretching vibrational-rotational mode increases as D2O vapor is 
being pumped into the sample compartment of the FTIR instrument. The spectra have been stacked for clarity. 
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Figure 21. FTIR spectra of 13C-A1-42 (A) and ApE3-42 (B) dried on a CaF2 window (black lines) and upon injection 
of D2O-saturated nitrogen for ~5 hours (blue to red). Amide I areas have been normalized. Time points of consecutive 
spectra can be determined from data of Fig. 21. The second derivatives of spectra corresponding to the dry and after 
five hours of vapor hydration for the A1-42 (C) and ApE3-42 (D). 
 Although both peptides transitioned from -helix to -sheet the kinetics of this transition 
were quite different. The ApE3-42 transition occurs much slower at first and then more rapidly later 
on. To examine the kinetics of this transition we plotted A/Aas well as the height of the amide 
II peak versus time (Figure 22). In the A1-42 for the first hour, the A1590/A1616 rapidly increased 
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while the amide II height rapidly diminished (Figure 22A). After an hour this trend continued but 
at a reduced rate. Conversely, the ApE3-42 transitions were sigmoidal in behavior. Little change 
occurred in the first hour, followed by rapid change in both amide II height and A1633/A1658 (Figure 
22B). The delayed -sheet formation of the ApE compared to the unmodified peptide agrees with 
our previous observations. 
 
Figure 22. Dependence of -structure formation (red) in 13C-A1-42 (A) and ApE3-42 (B) and amide II intensities (blue) 
on time of pumping D2O-saturated nitrogen into the sample compartment. 
Combined Sample -to- Transition 
 Following measurement of the individual peptides we examined the structural effects of 
combination of the peptides. Two peptide ratios were used a 9:1 (A1-42:ApE3-42) ratio and an 
equimolar ratio, as we used in previous experiments. Two samples were prepared and examined 
sequentially while exposed to the same vapor environment, the first has both peptides dried 
together on one side of the CaF2 FTIR window, in the other sample the two peptides are dried on 
opposite sides of the CaF2 window so the signal from both peptides is present in the spectra but 
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peptide interaction is not occurring (See Methods). When dried at either ratio, both A1-42 and 
ApE3-42 form -helix indicated by absorbance peaks at 1617-1619 and ~1658 cm-1 respectively 
(Figure 23 A,B). The -helix location is unchanged between separated and combined samples 
implying a lack of 13C:12C coupling. Therefore, we can conclude that in the -helical state the 
peptides are not interacting. Curiously in all samples the 13CA1-42 -helix absorbs at a lower 
intensity than would be expected from peptide ratios. 
 
Figure 23. FTIR spectra of the dried peptides at a 9:1 (A) and 1:1 (B) ratios. The teal spectra corresponds to separated 
peptides while the green is the peptides in combination. Amide I areas have been normalized. 
 Both peptides when either separated or combined at a 9:1 ratio underwent -to- transition 
in response to D2O vapor. After 5 hours of vapor hydration, the -helical peaks have diminished 
and in their place -sheet peaks corresponding to both peptides have formed, as well as a peak at 
1673 cm-1 corresponding to TFA with some likely contribution from ApE3-42 -turn (Figure 
24A,B). In the separated sample the ApE3-42 -sheet was located at 1625 cm-1 while in 
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combination it absorbed weaker and higher at 1639 cm-1. These peaks could normally be assigned 
to inter- and intramolecular -sheet respectively. However, the high molar ratio of 13CA1-42 means 
that this this upshift could also be caused by transition dipole coupling, thus further investigation 
is required. Examination of the second derivative of spectra taken after 5 hours of vapor hydration 
(Figure 24C,D), shows absorbance peaks at 1625 and 1639 cm-1 in both separate and combined 
samples. The presence of these peaks in both samples implies that both intra- and intermolecular 
-sheets are formed in both samples but co-incubation with unmodified A shifts structural 
propensity of ApE from inter- to intramolecular -sheet. In 13CA1-42 the -sheet is located at 
1585 and 1587 cm-1 in separate and combined samples respectively. These peaks indicate presence 
of intermolecular or cross -sheet, the small upshift in the combined sample is likely due to 13C:12C 
coupling with unlabeled ApE3-42. The lack of a structural shift in the 13CA-42 is expected, due to 
the high molar excess of A1-42 and the solid nature of the sample there is likely little interaction 
between most A1-42 peptides and ApE3-42. 
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Figure 24. FTIR spectra of ApE3-42 and 13C-A1-42 peptides at opposite sides of a CaF2 window (A) or combined on 
the same side of a window (B) at a 9:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue 
to red corresponds to injection of D2O-saturated nitrogen for ~5 hours. Amide I areas have been normalized. Time 
intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra 
after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides. 
The equimolar samples also undergo -to- transition. Diminishing of the ApE3-42 -helical peak 
throughout hydration again uncovers the peak located at 1673 cm-1 likely composed of both TFA 
from the 13CA1-42 and -turn of the ApE3-42 (Figure 25A,B). Along with this peak are peaks 
corresponding to -sheet of both peptides. After five hours of hydration from gas phase the -sheet 
peak of ApE3-42 the major peak is located at 1628 when separate and 1638 cm-1 when combined. 
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When separate the A-42 -sheet peak is located at 1586 cm-1 while in combination it shifts to 
1597 cm-1. For both peptides the former can be attributed to intermolecular -sheet while the latter 
can be attributed to intramolecular -sheet. Examination of the second derivative of 5 hour spectra 
show peaks corresponding to intra- and inter -sheets for both peptides (i.e. peaks at 1637, 1628, 
1597, and 1586 cm-1) indicating that the shifted peak comes from structural shifts and not simply 
13C:12C coupling (Figure 25C,D). Additionally, these spectra contain peaks at 1656-1654 and 
1617-1616 cm-1 these peaks likely represent residual -helix of ApE3-42 and A1-42 respectively, 
indicating incomplete -to- transition. This data along with the data from the 9:1 ratio indicate 
that ApE3-42 forms more intra- than inter-molecular -sheet in the presence of A1-42, while A1-
42 similarly forms more intra- than inter-molecular -sheet in the presence of ApE3-42. This 
relationship is demonstrated by overlaying the separated and combined samples spectra after 5 
hours of D2O hydration (Figure 26). 
To quantify this shift we examined the ratio Aintra/Ainter after five hours which gives the 
ratio of intra to inter--sheet present in the sample, which will henceforth refer to as R. Taking 
R comb/R sep allows quantification of the change in this ratio caused by peptide interaction (Table 
5). The values for the 9:1 13CA1-42 are not calculated as it did not form any significant fraction of 
intramolecular -sheet. For both A1-42 and ApE3-42 R comb/R sep is above 1 at both 9:1 and 1:1 
ratios indicating shifts in -sheet formation caused by peptide interaction. This is compelling 
evidence that the peptides act upon one another to mutually inhibit cross -sheet formation. 
Curiously, the structural components are consistent with their molar ratios after hydration in both 
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9:1 and 1:1 samples. This means that the altered ratios observed in dry samples is caused by a 
lowered extinction coefficient for 13CA1-42 -helical structure and not improper peptide ratios. 
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Figure 25. FTIR spectra of ApE3-42 and 13C-A1-42 peptides at opposite sides of a CaF2 window (A) or combined on 
the same side of a window (B) at a 1:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue 
to red corresponds to injection of D2O-saturated nitrogen for ~5 hours. Amide I areas have been normalized. Time 
intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra 
after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides. 
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Figure 26. FTIR spectra for 9:1 (A) and 1:1 (B) molar ratios taken after 5 hours of continuous vapor hydration. The 
teal spectra corresponds to separated peptides while the green is the peptides in combination. 
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Table 4. Quantitative data describing -helix to -sheet transitions in ApE3-42 and 13C-A1-42 peptides at opposite 
sides of a CaF2 window or combined together at one side of a window at 1:9 or 1:1 molar ratios.  is the shift in 
wavenumbers from -helix to -sheet and  is the difference between combined and separated samples. Aintra and 
Ainter correspond to the major b-sheet peaks as found experimentally and shown in the table. 
 9:1 (13CA1-42:ApE3-42) 1:1 (13CA1-42:ApE3-42) 
 ApE3-42 13CA1-42 ApE3-42 13CA1-42 
 → Transition 
Separate 1659→1625 1617→1585 1659→1628 1619→1586 
Peak Shift  
(cm-1) 
34 32 30 33 
Rsep (Aintra/Ainter) 
0.97 
- 
 0.95 
0.93 
 
Combined 1659→1639 1617→1587 1658→1638 1619→1597 
Peak Shift  20 30 20 22 
Rcomb 
(Aintra/Ainter) 
1.08 
- 
 1.05 1.41 
 14 2 10 11 
R comb/R sep 
1.11 - 1.11 1.51 
 
 The kinetics of → transition was examined by taking the ratio of the absorbance 
intensity at the peaks associated with -sheet in both separated and combined samples over the 
intensity of the -helical peak, and tracking it against time of hydration (Figure 27). At a 9:1 ratio 
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there is very little shift in the -sheet peak of the 13CA1-42 between the separated and combined 
samples as expected due to the low ratio of ApE and solid nature of the samples. When the 
kinetics of -sheet formation in both separated and combined samples is examined they closely 
resemble one another as well as the A1-42 individually, in that they undergo transition rapidly 
initially before then slowing but continuing to transition with time. The ApE3-42 initially 
underwent transition more slowly than the unmodified peptide, in agreement with previous 
observations. In both separate and combined samples the ApE3-42 forms more inter- than intra-
molecular -sheet. However, the difference between the two narrows in combined samples 
indicating a shift from inter- to intra--sheet formation (Black and white circles Figure 27 A,B). 
In the 1:1 samples the kinetics are similar with A1-42 transitioning rapidly at first and then slowing 
while ApE3-42 transition appeared to speed up with time (Figure 27 C,D). Examination of -sheet 
formation in combination yields strong evidence that the peptides mutually inhibit intermolecular 
-sheet formation in favor of intramolecular -sheet formation. For both peptides, when separated 
intermolecular -sheet formation is favored while the opposite is true in combined samples (White 
circles and squares are increased compared to colored in separate samples while the opposite is 
true in combination). Interestingly the effect of ApE3-42 on A1-42 appeared to be most pronounced 
after 3 hours, with the rate of intramolecular -sheet formation increasing greatly compared to the 
formation of intermolecular -sheet.  
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Figure 27. Changes in -sheet/-helix amide I intensity ratios with time of pumping D2O-saturated nitrogen. A, B: 
ApE3-42/13C-A1-42 = 1:9; C,D: ApE3-42/13C-A1-42 = 1:1. A, C: peptides are physically separated, i.e. are at opposite 
sides of a CaF2 window, B, D: peptides are combined at one side of a CaF2 window. Symbols in A are identical to B, 
and symbols in C is identical to D. Black graphs describe transitions in ApE3-42, red graphs describe transitions in 13C-
A1-42. ApE3-42 and 13C-A1-42 
 This data indicates that ApE3-42 and A1-42 mutually inhibit intermolecular -sheet 
formation of one another, instead promoting formation of intramolecular -sheet. This data agrees 
with previous observations of the ApE3-42 ability to inhibit cross -sheet formation of the A1-42 
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(Figures 7,9). Kinetic data shows a decelerated rate of intermolecular -sheet formation in mixed 
samples supporting this conjecture (Figure 27). Conceivably, this could be caused by intervention 
of non-identical peptide molecules into structures formed by the other peptide shifting the H-
bonding from intermolecular to intramolecular. Peptides forming intermolecular -sheets 
eventually go on to form mature fibrils while these intramolecular -sheets likely resemble the -
hairpins we described earlier (Figure 16). The presence of residual -helix agrees with earlier 
findings and supports this conclusion. It can therefore be concluded that A1-42 and ApE3-42 
mutually inhibit formation of intermolecular -sheet, instead promoting off-pathway formation of 
mixed / hairpins (Figure 28). This conclusion agrees with previous observations of delayed 
fibrillogenesis of mixed samples (Figure 5). 
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Figure 28. Scheme for aggregation of ApE3-42 (gray), A1-42 (red), and their combination, accompanied with an -
helix to -sheet transition. At the N-terminus of A1-42 there are 3 additional charges, a positive charge of the N-
terminal -amino group and 2 negative charges of the side chains of Asp1 and Glu3. Helices are shown as spirals, -
strands as arrows, and H-bonds as black bars. 
MTS Viability Assay 
 We next wished to examine the effect of these A hetero-oligomers on A aggregates 
through collaboration with Dr. Kenneth Teter and Dr. Lucia Cilenti. In this data the most toxic 
species is the equimolar combination of ApE3-42 and A1-42 at two hours of aggregation (Figure 
29). This is the time period where the greatest population of hetero-oligomer is thought to exist. 
This data demonstrates the enhanced cytotoxic properties of these hetero-oligomers. 
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Figure 29. Change in cellular viability caused by A aggregates as demonstrated by MTS assay. Studies were 
conducted in triplicate and normalized so that the control is equivalent to 100% viability. A peptides were added to 
peptides at a final concentration of 10 M for 28 or 50 hours. Ab peptides that had been aggregating in PBS at 37°C 
for 2 hours (First group) 4 hours (second group) and 24 hours (final group) 
A Mediated Membrane Calcium Leakage 
 The formation by A of calcium permeable membrane pores is a hypothesized mechanism 
of A mediated cytotoxicity in AD. To examine the effect of these oligomers, A aggregates were 
added to a solution containing calcium bound in unilamellar lipid vesicles composed of 60% POPC 
30% POPG and 10% cholesterol after 2 and 24 hours of aggregation. The release of calcium from 
vesicles was demonstrated via increase in fluorescence of Quin-2. Maximum fluorescence is 
demonstrated by popping all of the vesicles with triton-X. The results of this are striking, at two 
hours of aggregation A1-42 does not induce any greater calcium release than buffer control. 
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However, ApE3-42 as well as 9:1 and 1:1 combinations induce significant release of calcium 
(Figure 30A). At 24 hours of aggregation the combinations had a lesser effect than at two hours, 
consistent with pore formation by oligomers but not mature fibrils (Figure 30B). Curiously, the 
ApE3-42 actually had a greater effect on calcium release at 24 hours than 2 hours. Additionally, at 
24 hours the 9:1 had a greater effect than the 1:1. 
 
Figure 30. Vesicular calcium release as assayed by Quin-2. A peptides were added to vesicles after 2 hours (A) and 
24 hours (B) of aggregation via stirring at 37 °C. Data for release via A1-42 (blue), ApE3-42 (red), 9:1 (green) 1:1 (teal) 
and buffer control (black) are shown. Peptides were added following two measurements to establish a baseline, 0.5% 
Triton X-100 was added to the control after 6 measurements to disrupt vesicles and measure maximum fluorescence. 
 This data demonstrates that these hetero-oligomers do in-fact induce a significant drop in 
cellular viability compared to individual peptides. These hetero-oligomers also induced greater 
release of intra-vesicular calcium. The far greater effect of ApE3-42 at 24 hours as well as the 
greater effect of 9:1 than 1:1at 24 hours, is not consistent with toxicity data. To confirm these 
results follow up studies are being conducted. If confirmed, this data implies that formation of 
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calcium pores in lipid membranes may not be the primary A-mediated pathway of cellular 
dysfunction in AD. 
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CHAPTER FIVE: CONCLUSIONS 
 Recent evidence has shifted focus from fibrillar to soluble oligomeric species of A as the 
primary cytotoxic species in AD. Due to the difficulty of their study, namely their structural 
heterogeneity, dynamics, and polymorphic nature, little is known about the structure and formation 
of A oligomers. Pyroglutamylated A are major species of A in the AD brain displaying 
increased toxicity. Studies have demonstrated the ability of ApE3-42 to increase the toxicity of 
unmodified A in low molar ratio through structural changes however, little is known about the 
mechanism. 
This project sought to investigate A oligomer structure. In particular we aimed to examine 
the structural effect of ApE on unmodified A. Current evidence implicates these oligomers as 
the cytotoxic A agent in AD (38, 46). Pyroglutamylated A species make up a significant fraction 
of the soluble A in AD brains. ApE3-42 has been demonstrated to cause significant changes to 
oligomers of A1-42 and ApE3-42, altering both their structure and toxicity, even when it is present 
in low molar ratio (44). We first sought to examine the effects of ApE3-42 on the structure and 
fibrillization kinetics of A1-42. Data collected via CD indicate that ApE3-42 delays -sheet 
formation of the unmodified peptide in mixed samples. TEM images of the unmodified A 
collected after two hours of aggregation contain mature fibrils while samples of ApE and mixed 
samples contained greater numbers of globular aggregates. FTIR data indicates that ApE inhibits 
cross-sheet formation of the unmodified peptide, thus retarding fibrillogenesis. Inhibiting fibril 
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formation may increase the population of A oligomers or promote formation of off-pathway 
aggregates of enhanced toxicity.  
We next sought to characterize the early oligomers of ApE and unmodified A as well as 
the structural changes upon co-incubation. To further investigate the structure of A oligomers we 
utilized peptides selectively 13C-labeled at two specific segments K16L17V18 and V36G37G38V39. 
These allow site specific determination of protein secondary structure. Data was collected of A1-
42, ApE3-42, and, their equimolar combination labeled at two locations and in two buffers of 
different ionic content. This data indicates that early oligomers are composed of -helix, 
intramolecular -sheet, and -turn structure, and that the labeled segments were forming sheets. 
Changes in -helical content in different buffer conditions indicate that the a-helix is located at 
the N-terminus. Additionally, the carbon coupling of labeled residues indicates a lack of 13C:13C 
coupling giving both tertiary and quaternary structural insight. These data allow us to propose a 
possible structure for the monomeric A namely a -hairpin with an N-terminal -helix and a -
turn occurring downstream of K16L17V18. Data indicates that oligomerization likely occurs through 
non H-bonding interactions between neighboring -hairpin strands. 
After structural characterization of early peptides we sought greater detail on the early 
dynamics of oligomerization. In the plasma membrane as well as HFIP A peptides are -helical. 
In buffer they quickly form -sheets and begin to aggregate. We have already observed that ApE3-
42 inhibits this -sheet formation of the A1-42 in aqueous buffer. To observe these changes we 
gradually hydrated the peptides using D2O vapor. Upon exposure to vapor both peptides undergo 
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-to- transition but with different kinetics. A1-42 transitions rapidly in the first hour and 
continued to transition slowly afterwards, while ApE3-42 transitioned in a sigmoidal manner. When 
combined the peptides exerted a mutual effect upon one another to intermolecular -sheet 
formation instead forming intramolecular -sheets. Data from vesicle calcium release studies and 
MTS assays indicate that in combination the peptides have a more pronounced effect on cellular 
viability than the peptides individually and induce greater release of calcium than the unmodified 
peptide alone. Thus hybrid ApE and unmodified samples exhibit enhanced cytotoxicity possibly 
due to increased formation of off pathway mixed / oligomers instead of the intermolecular -
sheet structures that make up mature fibrils. These hetero-oligomers induce greater calcium release 
from lipid membranes and exert a greater effect on cellular viability than the unmodified A. 
Previous studies on A oligomers have found an antiparallel orientation while studies on 
mature fibrils show a parallel in-register orientation. In FTIR spectra antiparallel -sheet is 
indicated by a major peak 1636-1630 cm-1 and a minor peak 1680-1670 cm-1. Although several 
spectra appear to contain a peak corresponding to antiparallel -sheet (Figures 6, 16A,B), the low 
intensity of this peak makes it impossible to differentiate from other structural components. In 
ApE3-42 this peak is located in a similar location to -turn and TFA while in 13CA1-42 this peak 
(~1643-1633 cm-1) corresponds with ApE3-42 -sheet absorbance. Therefore, it is not possible to 
determine whether these oligomers are in a parallel or antiparallel orientation. Curve fitting of 
spectra indicate that -helical and -sheet fractions of peptides vary to a degree (Tables 3,4). This 
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indicates low barrier energy between these structures; and represents a possible source of A 
polymorphism. 
Significance 
 It is believed that the toxic A species in AD is formed during the transition from the -
helical structure formed prior to lipid membrane exit to the intermolecular -sheet structure found 
in mature fibrils. Here we characterized this transition as well as proposing a data-based model of 
early A monomers as well as aggregation. Data indicate that A1-42 and ApE3-42 mutually inhibit 
cross--sheet formation of one another instead forming mixed / hairpins. Inhibition of cross -
sheet formation delayed fibrillogenesis and lead to an increase in the population of globular 
aggregates. Studies have found oligomers of mixed / content to display enhanced cytotoxicity 
(114-116). These hetero-oligomers had a greater effect on the viability of PC12 cells than either 
peptide alone indicating their potent effect. Additionally, vesicle calcium release assays 
demonstrate that this effect may in part be due to enhanced formation of calcium permeable pores 
in lipid membranes. This work highlights the importance of hetero-oligomers in the pathogenesis 
of AD. This data gives insight into oligomer structure and formation as discussed in figure 1 
(Figure 31). 
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Figure 31. Update of Figure 1 using data collected during this work. Mixed populations of Ab1-42 and AbpE3-42 
promote formation of hetero-oligomers via a non-fibrillogenic pathway. These oligomers display increased 
cytotoxicity to PC12 cells possibly through the formation of calcium permeable membrane pores leading to loss of Ca 
2+ homeostasis. 
Future Studies 
 Targets for future study include A1-40 and its pyroglutamylated counterpart the ApE3-40. 
In vivo A populations are heterogeneous but little is known about the behavior of mixed peptide 
populations. These species are prevalent in the AD brain and examination should be conducted on 
whether they have similar structural effects upon one another. If they possess the same mutual 
inhibitory relationship, it is strong evidence that this effect may occur with other pyroglutamylated 
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A species. We also seek a method to stabilize oligomers for the time scales necessary for ssNMR 
analysis. Of particular interest is stabilization of oligomers formed in physiologically relevant 
conditions without using methods that may induce structural changes. High resolution structural 
data from ssNMR would represent strong supporting evidence for the -hairpin model proposed 
here. Follow-up studies should also be conducted to investigate inconsistencies between vesicular 
calcium release and cellular viability studies. 
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APPENDIX A: PEAK FITTING OF DRY SPECTRA 
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Peak fitting of Dry FTIR spectra. The original spectra (blue), peak fit (dotted red), and baseline 
(black) are shown. Fit peaks corresponding to alpha helix (orange) and the labeled segment (pink) 
are also shown. Peaks shown in grey are considered other in area concentration and correspond 
primarily to unordered structure. Peaks corresponding to side chain interactions are dotted grey 
and are not included in area calculations.  
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APPENDIX B: PEAK FITTING UNLABELED PEPTIDES 
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. Peak Fit Spectra of A1-42  ApE3-42  and their equimolar combination in 10 mM phosphate pD 
6.8 buffer labeled here as low salt as well as 50 mM phsosphate 50 mM NaCl pD 6.8 labeled here 
as high salt for 10, 60, and 120 minutes. The experimental measurement is shown in Blue while 
the Red dotted line is the sum of all components, fit peaks correspond to turn (green), -helix 
(orange), and -sheet (purple) unattributed peaks are shown in grey and are primarily composed 
of unordered structure. Peaks corresponding to side chain interactions are shown in dotted grey 
and are not included in area calculations. The second derivative of the experimental spectra is 
shown in black underneath. Total peptide concentration is 50 M. 
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APPENDIX C: PEAK FITTING OF LABELED PEPTIDES 
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. Curve fit spectra of 13C-labeled A1-42, ApE3-42  and their equimolar combination in 10 mM 
phosphate pD 6.8 buffer (low salt conditions) as well as 50 mM phsosphate 50 mM NaCl pD 6.8 
(physiological buffer) for 10, 60, and 120 minutes. Peptides were 13C- and 15N-labeled at either 
K16L17V18 or V36G37G38V39.The experimental measurement is shown in Blue while the Red dotted 
line is the sum of all components, fit peaks correspond to turn (green), -helix (orange), and -
sheet (purple) unattributed peaks are shown in grey and are primarily composed of unordered 
structure. Peaks corresponding to side chain interactions are shown in dotted grey and are not 
included in area calculations. The second derivative of the experimental spectra is shown in black 
underneath. Total peptide concentration is 50 M. 
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Table 5. Distribution of secondary structures in 50 mM phosphate 50 mM NaCl pD 6.8 as calculated by curve fitting. 
Numbers are the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak 
corresponding to the 13C-label in KLV/VGG and VGGV/KLV spectra. Components counted as other, primarily 
unordered structure, are not included in the table. 
High Salt A1-42 ApE3-42 1:1 
-turn 19.5 ± 8.3 27.7±5.0 22.1±3.5 
-helix 24.4±10.7 18.1±10.6 26.9±7.2 
-sheet 41.1±5.0 45.4±5.6 36.2±10.8 
13C-Label KLV 7.4±1.0 8.0±1.5 5.8±0.7 
13C-Label VGGV 10.3±0.8 9.9±0.4 10.4±0.5 
13C-Label Combination - - 6.1±2.8 
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Low Salt Conditions 
Table 6. Distribution of secondary structures in 10 mM phosphate pD 6.8 as calculated by curve fitting. Numbers are 
the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak corresponding 
to the 13C-label in KLV/VGG and VGGV/KLV spectra. Components counted as other, primarily unordered structure, 
are not included in the table. 
Low Salt A1-42 ApE3-42 1:1 
-turn 26.2±5.2 21.3±3.6 25.0±5.5 
-helix 21.8±7.9 21.5±8.1 15.3±6.0 
-sheet 34.2±9.5 35.2±10.2 36.5±8.5 
13C-Label KLV 4.9±0.6 6.7±0.5 6.3±0.6 
13C-Label VGGV 7.4±0.4 12.9±0.4 14.2±0.2 
13C-Label Combination - - 8.2±1.3 
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